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1. Prostate cancer 
Prostate cancer (PCa) is the most commonly diagnosed cancer and fifth leading cause 
of cancer-related death among men in western countries (1). The prostate is a gland 
located below the urinary bladder and in front of the rectum and contains a peripheral 
zone and transition zone. PCa usually arises in the peripheral glands. PCa shows 
heterogeneity in disease progression, with a considerable fraction of patients who have 
no symptoms and will not die from PCa, while a minority of patients has an aggressive 
disease course. In general, PCa is detected on the basis of elevated serum prostate-
specific antigen (PSA) level in the blood. Biopsies from the prostate gland confirm the 
diagnosis. The pathologist then assigns a grade, named Gleason score, to each tumor. 
Based on the PSA level, Gleason score and radiological information, the risk of disease 
for progression will be classified (Table 1). 
Table 1 Risk classification of prostate cancer. 
 Low-risk Intermediate-risk High-risk   
PSA <10 ng/mL 10-20 ng/mL >20 ng/mL any any 
Gleason < 7 7 > 7 any any 
 
 
TNM 
 
cT1 
(Clinically 
inapparent 
tumor) 
 to 
cT2a (Tumor 
involves one 
half of one 
lobe or less) 
cT2b (Tumor 
involves more 
than half of one 
lobe, but not both 
lobes) 
cT2c 
(Tumor 
involves 
both lobes) 
cT3-4 (Tumor 
extends through 
the prostatic 
capsule or invades 
adjacent 
structures) 
or  
cN+ (Regional 
lymph node 
metastasis) 
cM+ 
(Distant 
metastasis) 
 Localized Locally advanced Metastatic 
PSA = prostate-specific antigen; GS = Gleason score; TNM = Clinical Tumor Node Metastasis 
(TNM) classification of PCa. 
 
This classification guides clinicians to choose the proper treatment for PCa. When PCa 
is still organ confined, treatments may not be needed with only active surveillance, or 
patients can be offered with surgery (radical prostatectomy), radiation therapy with or 
without hormonal therapy. Although localized PCa can be well managed, a significant 
part (10-15%) of patients will eventually develop into the advanced stage of PCa or 
present de novo with this stage (5%) (2). At this stage, patients have the option of 
systemic treatment which usually includes androgen receptor (AR)-targeted treatment. 
Because the growth and survival of PCa cells is highly dependent on AR-signaling, 
patients initially respond well to either surgical and medical castration. However, 
 
 
eventually all patients will progress and develop into the final stage of PCa: metastatic 
castration-resistant prostate cancer (mCRPC), which is defined by either PSA or 
radiological progression, despite low level of testosterone (<50 ng/dl) (3). New 
therapeutic strategies for mCRPC are being offered to progressive patients, such as new 
combinations and/or new treatment sequences of second-generation anti-androgen 
therapy (enzalutamide, abiraterone, apalutamide), second line chemotherapy 
(cabazitaxel) and bone-targeting radionuclide therapy (radium-223) which have shown 
notable benefit for patient survival (4) (Figure 1). Despite this progress in the 
development of new drugs, mCRPC continues to be incurable, and patients will 
eventually die of the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Treatment landscape of prostate cancer 
 
2. Prostate cancer biomarkers  
As mentioned above, PSA remains the most used test to detect PCa to date despite its 
limited specificity and an elevated rate of overdiagnosis. New biomarkers which are 
able to improve (i) early detection of PCa, (ii) risk stratification, (iii) prognosis, and (iv) 
treatment monitoring as well as capture tumor heterogeneity and periodically reassess 
the molecular phenotype of PCa are needed. Accumulating studies show that liquid 
biopsies may achieve the clinical expectation which examine tumor cells or tumor 
genomic content in circulating fluids, such as circulating tumor cells (CTCs), 
circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) (5-7). These can be 
isolated from body fluids and analyzed for determining tumor-specific mutations, gene 
rearrangements and gene expression. EVs are small membrane vesicles secreted by 
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various types of cells into the extracellular environment (8). They were initially 
considered cell debris, however, in recent years, several studies suggest that EVs have 
a role in physiological and pathogenic processes (8, 9). They are enclosed by a 
phospholipid bilayer and contain DNA, RNA and proteins (10, 11). Different types of 
vesicles have been identified based on their biogenesis and size, such as exosomes, 
microvesicles and apoptotic bodies (12). EVs may reflect the tumor cell origin in terms 
of content (protein, RNA, DNA). Well-known PCa associated transcripts such as the 
kallikrein related peptidase 3 (PSA) gene and the transmembrane serine protease 2-ETS 
transcription factor ERG (TMPRSS2-ERG) fusion are detected inside urinary EVs in 
men with PCa (13, 14), thus measuring transcripts in PCa simple-derived EVs is 
expected to be a powerful method for the diagnosis, prognosis, and monitoring of PCa. 
However, this field is technically challenging, as majority of patient-derived EVs 
contain only low quantities of small RNA and it is uncertain whether the EVs are tumor-
specific.  
3. In vitro prostate cancer models 
Most preclinical studies of PCa depend heavily on two-dimensional (2D) cancer cell 
lines. These PCa cell lines are valuable in both fundamental and translational research. 
Their homogeneity and ease of handling makes them an ideal model system for large 
high-throughput experiments. However, 2D cell lines do not recapitulate the complex 
architecture of tumors nor the important interaction between tumor cells and their 
microenvironment. These limitations could lead to misinterpretation of involved 
molecular mechanisms or a failure when transitioning a new drug from the bench to the 
clinic. Animal models such as patient-derived xenografts (PDXs) allow for in vivo 
screening but these experiments are slow and resource-intensive. Furthermore, the 
success rate for developing PDX models for PCa is quite low. The recent advances in 
in vitro three-dimensional (3D) culture technologies, such as cell-line based spheroid 
culture, tumor organoid culture and precision-cut tumor slice culture have opened new 
avenues for the development of more reliable in vitro PCa models. The limited cell-cell 
interactions in 2D monolayer cultures could induce major changes in cellular 
physiology. 3D spheroid culture of the same cells may represent the original tumor 
more faithfully. Although they capture some features of tumor cell biology better than 
2D culture, they fail to mimic tumor heterogeneity. Another 3D model is organoid 
culture. Tissue-derived adult stem cells can be embedded in a 3D matrix and grown into 
self-organizing organotypic structures, termed organoids (15). Similar technology 
allows 3D culture of tumor cells in spheroid structures - referred to as tumor organoids. 
Organoid cultures can represent (part of) the heterogeneity of the original tumor. Some 
drawbacks are also clear: 1. lack of stromal cells in the majority of cases, 2. the 
requirement of a collagen gel for 3D culturing complicates potential drug screening and 
makes culturing more labor intensive, 3. it is not completely clear how well these tumor 
organoids recapitulate structural and functional aspects of their in vivo counterpart 
tumors. More recently, organoids have been co-cultured with additional cellular or 
microbial elements in order to increase the comparability to in vivo tumors (16). Finally, 
 
 
as an alternative 3D model, ex vivo culturing of tumor slices represent a solid model 
system for drug sensitivity testing due to its relatively short generation time and 
reflection of the natural tumor microenvironment. Starting from the 1970s, various 
studies have described ex vivo culture systems for PCa tumors. This has resulted in the 
development of different tumor culture methods, ranging from direct culturing of 1-2 
mm3 human tissue samples in cell culture medium to more recently developed 
techniques to culture precision-cut tissue slices on various scaffolds and supporting 
filters, such as gelatin, collagen sponges, titanium mesh inserts or cell strainers (17-20). 
Ex vivo culture of prostate tumors faces many challenges, such as the lack of long-term 
tumor cell viability, low cancer cells proliferation and overgrowth with normal basal 
cells, but it has the potential as a short-term personalized culture system. Taken together, 
each model has its own pro and cons, therefore, models should be chosen based on the 
specific situation and research question (Table 2). 
Table 2 Comparison of in vitro PCa tumor models. 
 Cell Spheroid Organoid Tissue 
slice 
Establishment difficulty high low high med 
Maintenance difficulty low low med high 
Morphology preservation -/+ + + + + + + 
Viability maintenance +++ + + + + + + 
Microenvironment 
preservation 
- - + + + + + 
Success rate of initiation + + + + + + + + + 
Drug screening + + + + + + + + + 
Amenable to genetic 
modification 
+ + + + + + + + - 
Matched normal controls - - + ++ 
Costs low low high low 
Respective features were judged as best (+++), suitable (++), possible (+) or unsuitable (−). 
 
4. Radiation therapy 
Radiation therapy is the first-line treatment for localized PCa, which can be 
administered as either external beam radiation therapy (EBRT) or brachytherapy, in 
which a radioactive source is implanted in or close to tumor. Conventionally, 
fractionated EBRT up to 78 Gy in 39 fractions of 2 Gy was introduced for patients with 
localized PCa (4). Irradiation (IR) induces cell death by the production of reactive 
oxygen species (ROS) as well as by direct ionization of the DNA which leads to single-
strand breaks (SSBs) and double-strand breaks (DSBs). Depending on the risk group of 
PCa patients, single or combination treatment with androgen deprivation therapy (ADT) 
will be provided for patients. For high-risk PCa, adjuvant ADT is recommended as 
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combination treatment, which significantly improves overall cancer-related survival 
(21, 22). Based on its beneficial effects, this combination is currently the standard of 
care for locally advanced PCa. Even though combination strategy has been shown to 
improve the overall therapeutic outcome compared to IR alone, the effect is rather 
modest. Clinicians still face the difficulty that biomarkers for selection of patients that 
will benefit from this combination are still lacking. 
5. DNA damage response  
Since outcome of radiotherapy relies on the induction of DNA damage and its 
subsequent repair, it is evident that the status of the DNA damage response (DDR) is 
one of the important factors that can predict treatment outcome. Besides IR, the DNA 
is constantly damaged by exogenous sources as well as by endogenous DNA-damaging 
agents (23, 24) as DNA is an intrinsically instable molecule and vulnerable to chemical 
modifications (23). Incorrect or failed repair of damaged DNA can lead to genetic 
alterations, instability and give rise to cancer. DNA damage comes in various forms, 
including base oxidation, deamination, alkylation, interstrand crosslinks, adduct 
formation, SSBs, and DSBs. To prevent genomic instability and deal with enormous 
load of DNA damage, multiple distinct repair pathways have been identified to cope 
with the divergent types of damages mentioned above such as base excision repair 
(BER), nucleotide excision repair (NER), mismatch repair (MMR), and DSBs repair 
(25). DSBs are the most relevant in the context of cancer treatment, as many traditional 
anti-cancer treatments induce DSBs which is the most toxic and lethal form of DNA 
damage. DSB repair consists of two main pathways: homologous recombination (HR) 
and non-homologous end-joining (NHEJ). NHEJ is the major contributor to DSBs 
repair that simply joins the two ends of broken DNA and can be performed in all cell 
cycle phases. HR uses the sister chromatids as a template to repair DSBs, thus it only 
happens in the S and G2 phases of the cell cycle and is highly accurate (Figure 2) (25). 
Clinical and preclinical studies have revealed that alterations in DDR pathways play a 
role in PCa etiology and progression, especially in advanced stage (26-29). The efficacy 
of DNA-damaging anti-cancer treatments can be affected depending on the exact repair 
pathway deficiency, opening a window of opportunity to individualize cancer treatment 
based on tumor characteristics. For example, patients harboring DNA repair defects 
may have increased radiosensitivity or can be targeted by specific treatments, such as 
poly(ADP-ribose) polymerase (PARP) inhibitors (30). Future studies are needed to 
broaden our understanding of DDR in PCa, as well as to determine how this knowledge 
can be used to improve therapeutic approaches.  
6. Scope of the thesis 
This thesis describes several in vitro 3D PCa models and explores the mechanism of 
DNA repair and its regulation by AR signaling in PCa. Chapter 2 provides an overview 
of the importance of preclinical and clinical research for DDR in PCa and discusses 
how these recent and ongoing studies will help to improve diagnostic, prognostic and 
therapeutic approaches for PCa management. Chapter 3 describes an ex vivo culture 
 
 
system for PCa PDX tumor-derived tissue slices. We characterized and validated the 
system by testing drugs on tumor slices with different genotypes. In chapter 4, we 
evaluated the use of EVs in monitoring PCa treatment response by investigating EVs 
from tissue slice culture medium. The quantity and quality of RNA from EVs were 
characterized and gene expression alteration upon anti-androgen treatment was 
compared to its cell of origin. In chapter 5, we report on the generation of PCa PDX-
derived organoid cultures. By establishing the PCa organoids culture, we evaluated 
radiosensitivity on these novel models and compared to tissue slices models. Finally, 
in chapter 6, we investigate how radiosensitivity can be enhanced by anti-androgen 
treatments. This combination is used in a clinical setting, but its mechanisms remains 
unclear and controversial. We provide evidence that NHEJ is directly regulated by AR 
signaling.  
 
Figure 2 Double-strand break repair. 
Double-strand break repair consists two major pathways: non-homologous end-joining (NHEJ) and 
homologous recombination (HR). NHEJ occurs during all cell cycle phases and simply rejoins 
broken DNA ends. HR is restricted to the S and G2 phases of the cell cycle as it makes use of the 
sister chromatid to accurately repair broken DNA. 
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in chapter 6, we investigate how radiosensitivity can be enhanced by anti-androgen 
treatments. This combination is used in a clinical setting, but its mechanisms remains 
unclear and controversial. We provide evidence that NHEJ is directly regulated by AR 
signaling.  
 
Figure 2 Double-strand break repair. 
Double-strand break repair consists two major pathways: non-homologous end-joining (NHEJ) and 
homologous recombination (HR). NHEJ occurs during all cell cycle phases and simply rejoins 
broken DNA ends. HR is restricted to the S and G2 phases of the cell cycle as it makes use of the 
sister chromatid to accurately repair broken DNA. 
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Abstract 
Clinical and preclinical studies have revealed that alterations in DNA damage response 
(DDR) pathways may play an important role in prostate cancer (PCa) etiology and 
progression. These alterations can influence PCa responses to radiotherapy and anti-
androgen treatment. The identification of DNA repair gene aberrations in PCa has 
driven the interest for further evaluation whether these genetic changes may serve as 
biomarkers for patient stratification. In this review, we summarize the current 
knowledge on DDR alterations in PCa, their potential impact on clinical interventions 
and prospects for improved management of PCa. We particularly focus on the influence 
of DDR gene mutations on PCa initiation and progression and describe the underlying 
mechanisms. A better understanding of these mechanisms, will contribute to better 
disease management as treatment strategies can be chosen based on the specific disease 
properties, since a growing number of treatments are targeting DDR pathway 
alterations (such as Poly(ADP-ribose) polymerase inhibitors). Furthermore, the 
recently discovered crosstalk between the DDR and androgen receptor signaling opens 
a new array of possible strategies to optimize treatment combinations. We discuss how 
these recent and ongoing studies will help to improve diagnostic, prognostic and 
therapeutic approaches for PCa management. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Prostate cancer (PCa) is the second most common cancer in men and the fourth most 
common tumor type worldwide (1). Although organ-confined disease can be well 
managed, curative therapeutic options for disseminated disease are limited. First-line 
therapy for disseminated PCa is androgen deprivation therapy (ADT) that prevents 
androgen receptor (AR) pathway signaling as most PCas are dependent on activated 
AR signaling for cell survival (2, 3). In time, patients under ADT may progress to 
castration-resistant PCa (CRPC), requiring first line chemotherapy (commonly 
docetaxel) (4). New therapeutic strategies for CRPC are being offered to patients, such 
as new combinations and sequences of second-generation anti-androgen therapy 
(enzalutamide, abiraterone, apalutamide) or second line chemotherapy (cabazitaxel), 
which have shown notable benefit for patient survival (4). In addition, promising new 
treatment modalities, such as Radium-223 and prostate-specific membrane antigen 
(PSMA)-directed radioligand therapy, are being exploited for patients with (bone) 
metastatic disease. Despite this progress in the development of new drugs, CRPC 
continues to be incurable, and drug resistance remains an issue. 
Clinical and preclinical studies have revealed that alterations in DNA damage 
response (DDR) pathways play a role in PCa etiology and progression, especially in 
CRPC patients (5-10). These DNA repair defects may be targeted by specific treatments, 
such as Poly(ADP-ribose) polymerase (PARP) inhibitors (11). Moreover, several 
studies provided evidence that AR signaling links to the DDR in PCa cells, which may 
have relevance for the first line disease management using ADT and AR-targeted agents 
(12, 13). In this review, we summarize the current knowledge of DDR alterations in 
PCa, the AR-DDR crosstalk and the potential exploitation of DDR targeting drugs to 
improve clinical interventions. 
2. DNA damage response pathways 
DNA damage has emerged as a major culprit in cancer initiation and progression. The 
DNA is constantly damaged by exogenous sources such as genotoxic chemicals, 
ultraviolet (UV) and ionizing radiation (IR), as well as by endogenous DNA damaging 
agents, such as reactive oxygen and nitrogen species (14, 15). These sources will induce 
various damages to the DNA, including base oxidation, deamination, alkylation, 
interstrand crosslinks, adduct formation, single-strand breaks (SSBs) and double-strand 
breaks (DSBs). Additionally, spontaneous DNA damage is induced during replication. 
Collisions of the replication fork with DNA-binding proteins or the transcription 
machinery are the most common causes leading to replication fork stalling or collapse, 
which in turn induces DNA damage (16, 17). Incorrect or failed repair of damaged 
DNA can lead to genetic alterations. Important consequences of genetic alterations are 
loss of tumor suppressor genes and activation of oncogenes, which may trigger the 
development of malignant cells or increase aggressiveness of tumor cells. Normal cells 
maintain genomic integrity using various DDR mechanisms to repair damaged DNA or 
induce cell death. The concept of DDR has been introduced to describe a series of 
biological reactions including DNA lesion site detection, repair protein recruitment, 
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damage repair, cell cycle checkpoint control and cell death pathways. 
The highly diverse spectrum of DNA lesions can be repaired by a number of 
different DNA repair pathways, which have been reviewed extensively elsewhere (18-
20). In short, base excision repair (BER) involves multiple enzymes to excise and 
replace a single damaged nucleotide base, such as an oxidized base, but also an SSB 
(21). Mismatch repair (MMR) is mainly involved in repair of base mismatches and 
insertions/deletions that can occur during replication and recombination (22). The 
Fanconi anemia (FA) pathway repairs DNA interstrand crosslinks in the genome (23). 
DSBs are resolved either by high-fidelity homologous recombination (HR) or error-
prone non-homologous end joining (NHEJ). The HR pathway is only active when the 
cell is in the S/G2 cell cycle stage since it requires the presence of the sister chromatid 
as a repair template (24). DSBs can be generated during replication when the replication 
fork encounters a DNA lesion and these breaks are exclusively repaired by HR. NHEJ 
is active during all cell cycle stages and functions by directly ligating broken DNA ends. 
Since no template is used during NHEJ, repair via this pathway is error prone (Figure 
1) (24). After DNA damage induction, depending on the severity of the lesion and repair 
capacity, cells will continue to proliferate if damages are repaired, or cells stop 
proliferation, become senescent, or undergo programmed cell death (apoptosis) to 
remove damaged DNA from the cellular population (25). Alterations in any of these 
pathways can result in genomic instability and consequently predispose to cancer, affect 
disease progression and/or influence therapy efficacy. Nonetheless, impaired DNA 
repair can also be a possible Achilles heel of the cancer that can be exploited for 
treatment (26). 
 
Figure 1 DNA double strand (DSB) and single strand break (SSB) repair pathways.  
The majority of the DSBs are repaired by the error-prone Non-Homologous End-Joining pathway 
(NHEJ, available during all cell cycle stages) and a smaller fraction of the DSBs are repaired via 
 
 
Homologous Recombination (HR, only during S/G2 cell cycle stages). SSBs are repaired by the 
Single Strand Break Repair pathway (available during all cell cycle stages). During DNA replication 
can an unrepaired SSB be converted into a DSB which can then only be repaired by HR. 
 
3. Molecular mechanisms underlying PCa risk 
Multiple studies have indicated that germline mutations in DNA repair genes are 
associated with a higher risk of developing PCa. The individuals at risk have one 
inherited dysfunctional allele of the DNA repair gene and a second event (mutation or 
epigenetic silencing) can cause inactivation of the functional allele. The most common 
germline mutated DDR genes in primary PCa or CRPC are found in the Breast Cancer 
1 and 2 (BRCA1 and BRCA2) genes. Similar to the role of mutations in BRCA1/2 in the 
development of breast cancer and ovarian cancer (14), various studies have shown that 
inactivating BRCA1/2 mutations, predominantly BRCA2, increase predisposition to 
PCa (Table 1) (7-9, 27-29). BRCA1/2 are tumor suppressor genes and both encode large 
proteins which act in multiple cellular pathways. BRCA1 and BRCA2 are both involved 
in the HR pathway (30, 31), while BRCA1 has also been found to have other functions 
(32). Loss-of-function mutations in BRCA1/2 lead to a deficiency in error-free HR 
repair. Therefore, DSBs will be repaired alternatively by other non- conservative and 
potentially mutagenic mechanisms, such as the NHEJ pathway. The resulting genomic 
instability (chromosomal translocations and deletions) and mutations may be the 
underlying mechanism of BRCA1/2 associated cancers (33, 34). This could increase the 
risk of acquiring fusion genes, such as the TMPRSS2/ERG fusion that is found in 40-
50% of PCa cases (35), although no solid evidence has been acquired to link BRCA1/2 
mutation status to this fusion. Furthermore, the reason why BRCA1/2 mutations are 
particularly associated with specific cancer types, such as breast, ovarian and PCa 
remains unknown.  
Francis et al. showed that BRCA2 can act as a tumor suppressor in the prostate 
(36). Using a genetically engineered mouse model, it was found that deletion of Brca2 
in prostate epithelia resulted in focal hyperplasia and low-grade prostate intraepithelial 
neoplasia (PIN) in animals over 12 months old. Epithelial cells in these lesions showed 
an increase in DNA damage. The evidence that other inherited gene mutations in DSB 
repair genes, such as BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1) and 
Nibrin (NBS1), are also associated with PCa has been documented less extensively (6, 
8). Besides DSB gene alterations, mutations in the MMR genes MutS homolog 2 and 6 
(MSH2 and MSH6) are also associated with increased PCa risk (7, 27). MMR mutations 
would mainly cause point mutations or small insertions and deletions of short repetitive 
sequences of DNA which may result in microsatellite instability (37). Therefore, 
underlying mechanisms of PCa can be linked to Lynch syndrome, a hereditary 'non-
polyposis'-colorectal carcinoma that is caused by MMR pathway mutations. The 
increased risk of PCa in MMR mutation carriers and in families with Lynch syndrome 
provide the rationale to include PCa in the Lynch syndrome tumor spectrum, which is 
relevant for risk estimates and surveillance recommendations in MMR mutation 
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1) (24). After DNA damage induction, depending on the severity of the lesion and repair 
capacity, cells will continue to proliferate if damages are repaired, or cells stop 
proliferation, become senescent, or undergo programmed cell death (apoptosis) to 
remove damaged DNA from the cellular population (25). Alterations in any of these 
pathways can result in genomic instability and consequently predispose to cancer, affect 
disease progression and/or influence therapy efficacy. Nonetheless, impaired DNA 
repair can also be a possible Achilles heel of the cancer that can be exploited for 
treatment (26). 
 
Figure 1 DNA double strand (DSB) and single strand break (SSB) repair pathways.  
The majority of the DSBs are repaired by the error-prone Non-Homologous End-Joining pathway 
(NHEJ, available during all cell cycle stages) and a smaller fraction of the DSBs are repaired via 
 
 
Homologous Recombination (HR, only during S/G2 cell cycle stages). SSBs are repaired by the 
Single Strand Break Repair pathway (available during all cell cycle stages). During DNA replication 
can an unrepaired SSB be converted into a DSB which can then only be repaired by HR. 
 
3. Molecular mechanisms underlying PCa risk 
Multiple studies have indicated that germline mutations in DNA repair genes are 
associated with a higher risk of developing PCa. The individuals at risk have one 
inherited dysfunctional allele of the DNA repair gene and a second event (mutation or 
epigenetic silencing) can cause inactivation of the functional allele. The most common 
germline mutated DDR genes in primary PCa or CRPC are found in the Breast Cancer 
1 and 2 (BRCA1 and BRCA2) genes. Similar to the role of mutations in BRCA1/2 in the 
development of breast cancer and ovarian cancer (14), various studies have shown that 
inactivating BRCA1/2 mutations, predominantly BRCA2, increase predisposition to 
PCa (Table 1) (7-9, 27-29). BRCA1/2 are tumor suppressor genes and both encode large 
proteins which act in multiple cellular pathways. BRCA1 and BRCA2 are both involved 
in the HR pathway (30, 31), while BRCA1 has also been found to have other functions 
(32). Loss-of-function mutations in BRCA1/2 lead to a deficiency in error-free HR 
repair. Therefore, DSBs will be repaired alternatively by other non- conservative and 
potentially mutagenic mechanisms, such as the NHEJ pathway. The resulting genomic 
instability (chromosomal translocations and deletions) and mutations may be the 
underlying mechanism of BRCA1/2 associated cancers (33, 34). This could increase the 
risk of acquiring fusion genes, such as the TMPRSS2/ERG fusion that is found in 40-
50% of PCa cases (35), although no solid evidence has been acquired to link BRCA1/2 
mutation status to this fusion. Furthermore, the reason why BRCA1/2 mutations are 
particularly associated with specific cancer types, such as breast, ovarian and PCa 
remains unknown.  
Francis et al. showed that BRCA2 can act as a tumor suppressor in the prostate 
(36). Using a genetically engineered mouse model, it was found that deletion of Brca2 
in prostate epithelia resulted in focal hyperplasia and low-grade prostate intraepithelial 
neoplasia (PIN) in animals over 12 months old. Epithelial cells in these lesions showed 
an increase in DNA damage. The evidence that other inherited gene mutations in DSB 
repair genes, such as BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1) and 
Nibrin (NBS1), are also associated with PCa has been documented less extensively (6, 
8). Besides DSB gene alterations, mutations in the MMR genes MutS homolog 2 and 6 
(MSH2 and MSH6) are also associated with increased PCa risk (7, 27). MMR mutations 
would mainly cause point mutations or small insertions and deletions of short repetitive 
sequences of DNA which may result in microsatellite instability (37). Therefore, 
underlying mechanisms of PCa can be linked to Lynch syndrome, a hereditary 'non-
polyposis'-colorectal carcinoma that is caused by MMR pathway mutations. The 
increased risk of PCa in MMR mutation carriers and in families with Lynch syndrome 
provide the rationale to include PCa in the Lynch syndrome tumor spectrum, which is 
relevant for risk estimates and surveillance recommendations in MMR mutation 
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carriers (38). 
Table 1 Germline DDR mutations increase PCa risk 
BRCA1/2: Breast Cancer 1 and 2; MSH2/6: MutS protein homolog 2 and 6; MLH1: MutL homolog 
1; PMS2: PMS1 homolog 2; BRIP1: BRCA1 interacting protein C-terminal helicase1; HR: 
homologous recombination; MMR: mismatch repair; FA: fanconi anemia pathway. 
 
4. DDR defects in PCa 
4.1 DDR defects in primary PCa 
The clinical behavior of localized PCa is highly variable: while some men have 
aggressive cancer leading to metastasis and death, many others have indolent cancers 
and these men can be cured by local therapy or may be safely observed without 
treatment (39). Several studies have identified primary PCa tumors harboring a 
diversity of DDR gene alterations (summarized in table 2) (40-45). These studies 
identified a heterogeneous panel of repair defects caused by homozygous mutations or 
copy number alterations in primary prostate tumors compared to paired normal tissue 
in Ataxia–telangiectasia mutated (ATM), BRCA2, RAD51, mediator of DNA damage 
checkpoint 1 (MDC1), PARP1 and FA complementation group D2 (FANCD2), 
although the level of incidence varied between the studies. This considerable 
heterogeneity of repair defect prevalence among different studies could at least in part 
be attributed to the diversity of the study populations, as the genetic background can 
differ significantly between indolent, non-symptomatic and progressive PCa (46-48). 
Loss-of-function DDR gene mutations can contribute to a more aggressive PCa 
phenotype with a higher probability of nodal involvement and distant metastasis (5, 49-
Gene Pathway Relevance 
BRCA1 (9) HR Deleterious BRCA1 mutations confer a relative PCa risk 
of 3.75, and a 8.6% cumulative risk by age 65. 
BRCA1 and BRCA2 
(28, 49, 61) 
HR BRCA2 mutation carriers have an increased risk of PCa 
and a higher histological grade. BRCA1 and BRCA2 
mutation carriers had a higher risk of recurrence and PCa-
specific death. 
MSH2, MLH1 and 
MSH6 (27) 
MMR Increased PCa risk. Evidence to link PCa to Lynch 
syndrome. 
MLH1, MSH2, 
MSH6, and PMS2 
(7) 
MMR MMR genes may confer a high risk of PCa when mutated. 
MSH2, MLH1 and 
MSH6 (29) 
MMR MMR gene mutation carriers have at least a twofold or 
greater increased risk of developing MMR-deficient PCa 
where the risk is highest for MSH2 mutation carriers.  
BRIP1 (8) FA Truncating mutations in BRIP1 might confer an increased 
risk of PCa  
 
 
51). This aggressive phenotype was also reported in patients harboring BRCA1/2 and 
ATM combined mutations (52) and NBS1 mutations alone (6). Recent clinical data have 
shown a strong prognostic value of a DDR mutation signature which may be used for 
risk stratification for high-risk PCa patients. Treatment outcome for BRCA1/2 mutation 
carriers showed worse outcomes for these patients than non-carriers when 
conventionally treated with surgery or radiation therapy (53)  
The studies discussed above found DDR mutations in primary PCa, with a 
heterogeneous and overall low mutation rate. However, a direct (mechanistic) link 
between these mutations and PCa predisposition and treatment has not yet been 
established. As primary PCa is typically well managed and not lethal, it will therefore 
be of more interest to focus on the landscape of DDR defects in advanced PCa. 
Table 2 Prevalence of selected DDR gene alteration in primary PCa 
Study Pathway Barbieri 
et al (29) 
 
Baca et 
al (30) 
 
Cancer 
Genome 
Atlas (31) 
Fraser et 
al (95) 
Ren et al 
(32) 
Total 
Patients 
(n) 
 112 57 333 449 65 1017 
ATM General 2.8% (3) 12.5%(7) 7.2%(24) 1.8%(8) 3.1%(2) 4.3%(44) 
ATR  1.8%(1) 2.4%(8)  5%(3) 1.2%(12) 
BRCA1  
HR 
1.8%(2)  1.2%(4)  1.5%(1) 0.69%(7) 
BRCA2  7.1%(4) 3.3%(11)  1.5%(1) 1.58%(16) 
RAD51  3.6%(2) 2.1%(7)   0.88%(9) 
PARP1 BER  3.6%(2) 3.0%(10)  3.1%(2) 1.38%(14) 
MLH1 MMR   0.3%(1)   0.09%(1) 
MSH2   1.5%(5)   0.49%(5) 
FANCD2 FA  1.8%(1) 0.9%(3)  1.5%(1) 0.49%(5) 
All genes  4.6% 30.4% 21.9% 1.8% 15.7% 11.1% 
Data was acquired from The Memorial Sloan Kettering cBioportal database (http://cbioportal.org) 
for certain DDR genes from different study. ATM: Ataxia–telangiectasia mutated serine/threonine 
kinase; ATR: ATM and RAD3-related serine/threonine kinase; BRCA1/2: Breast Cancer 1 and 2; 
RAD51: RAD51 recombinase; PARP1: poly(ADP-ribose) polymerase 1; MLH1: MutL homolog 1; 
MSH2: MutS protein homolog 2; FANCD2: FA complementation group D2. HR: homologous 
recombination; BER: base excision repair; MMR: mismatch repair; FA: fanconi anemia pathway. 
 
4.2 DDR defects in mCRPC 
An enrichment of DDR gene alterations can be found during PCa progression, 
especially when the disease develops into metastatic CRPC (mCRPC) (summarized in 
Table 3) (54-56). Heavily pre-treated mCRPC contained more genetic alterations in 
DDR genes (46%) than treatment-naive high grade localized tumors (27%) (54). A 
multi-institutional clinical sequencing study revealed that the majority of affected 
individuals with CRPC harbor clinically actionable homozygous molecular alterations, 
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carriers (38). 
Table 1 Germline DDR mutations increase PCa risk 
BRCA1/2: Breast Cancer 1 and 2; MSH2/6: MutS protein homolog 2 and 6; MLH1: MutL homolog 
1; PMS2: PMS1 homolog 2; BRIP1: BRCA1 interacting protein C-terminal helicase1; HR: 
homologous recombination; MMR: mismatch repair; FA: fanconi anemia pathway. 
 
4. DDR defects in PCa 
4.1 DDR defects in primary PCa 
The clinical behavior of localized PCa is highly variable: while some men have 
aggressive cancer leading to metastasis and death, many others have indolent cancers 
and these men can be cured by local therapy or may be safely observed without 
treatment (39). Several studies have identified primary PCa tumors harboring a 
diversity of DDR gene alterations (summarized in table 2) (40-45). These studies 
identified a heterogeneous panel of repair defects caused by homozygous mutations or 
copy number alterations in primary prostate tumors compared to paired normal tissue 
in Ataxia–telangiectasia mutated (ATM), BRCA2, RAD51, mediator of DNA damage 
checkpoint 1 (MDC1), PARP1 and FA complementation group D2 (FANCD2), 
although the level of incidence varied between the studies. This considerable 
heterogeneity of repair defect prevalence among different studies could at least in part 
be attributed to the diversity of the study populations, as the genetic background can 
differ significantly between indolent, non-symptomatic and progressive PCa (46-48). 
Loss-of-function DDR gene mutations can contribute to a more aggressive PCa 
phenotype with a higher probability of nodal involvement and distant metastasis (5, 49-
Gene Pathway Relevance 
BRCA1 (9) HR Deleterious BRCA1 mutations confer a relative PCa risk 
of 3.75, and a 8.6% cumulative risk by age 65. 
BRCA1 and BRCA2 
(28, 49, 61) 
HR BRCA2 mutation carriers have an increased risk of PCa 
and a higher histological grade. BRCA1 and BRCA2 
mutation carriers had a higher risk of recurrence and PCa-
specific death. 
MSH2, MLH1 and 
MSH6 (27) 
MMR Increased PCa risk. Evidence to link PCa to Lynch 
syndrome. 
MLH1, MSH2, 
MSH6, and PMS2 
(7) 
MMR MMR genes may confer a high risk of PCa when mutated. 
MSH2, MLH1 and 
MSH6 (29) 
MMR MMR gene mutation carriers have at least a twofold or 
greater increased risk of developing MMR-deficient PCa 
where the risk is highest for MSH2 mutation carriers.  
BRIP1 (8) FA Truncating mutations in BRIP1 might confer an increased 
risk of PCa  
 
 
51). This aggressive phenotype was also reported in patients harboring BRCA1/2 and 
ATM combined mutations (52) and NBS1 mutations alone (6). Recent clinical data have 
shown a strong prognostic value of a DDR mutation signature which may be used for 
risk stratification for high-risk PCa patients. Treatment outcome for BRCA1/2 mutation 
carriers showed worse outcomes for these patients than non-carriers when 
conventionally treated with surgery or radiation therapy (53)  
The studies discussed above found DDR mutations in primary PCa, with a 
heterogeneous and overall low mutation rate. However, a direct (mechanistic) link 
between these mutations and PCa predisposition and treatment has not yet been 
established. As primary PCa is typically well managed and not lethal, it will therefore 
be of more interest to focus on the landscape of DDR defects in advanced PCa. 
Table 2 Prevalence of selected DDR gene alteration in primary PCa 
Study Pathway Barbieri 
et al (29) 
 
Baca et 
al (30) 
 
Cancer 
Genome 
Atlas (31) 
Fraser et 
al (95) 
Ren et al 
(32) 
Total 
Patients 
(n) 
 112 57 333 449 65 1017 
ATM General 2.8% (3) 12.5%(7) 7.2%(24) 1.8%(8) 3.1%(2) 4.3%(44) 
ATR  1.8%(1) 2.4%(8)  5%(3) 1.2%(12) 
BRCA1  
HR 
1.8%(2)  1.2%(4)  1.5%(1) 0.69%(7) 
BRCA2  7.1%(4) 3.3%(11)  1.5%(1) 1.58%(16) 
RAD51  3.6%(2) 2.1%(7)   0.88%(9) 
PARP1 BER  3.6%(2) 3.0%(10)  3.1%(2) 1.38%(14) 
MLH1 MMR   0.3%(1)   0.09%(1) 
MSH2   1.5%(5)   0.49%(5) 
FANCD2 FA  1.8%(1) 0.9%(3)  1.5%(1) 0.49%(5) 
All genes  4.6% 30.4% 21.9% 1.8% 15.7% 11.1% 
Data was acquired from The Memorial Sloan Kettering cBioportal database (http://cbioportal.org) 
for certain DDR genes from different study. ATM: Ataxia–telangiectasia mutated serine/threonine 
kinase; ATR: ATM and RAD3-related serine/threonine kinase; BRCA1/2: Breast Cancer 1 and 2; 
RAD51: RAD51 recombinase; PARP1: poly(ADP-ribose) polymerase 1; MLH1: MutL homolog 1; 
MSH2: MutS protein homolog 2; FANCD2: FA complementation group D2. HR: homologous 
recombination; BER: base excision repair; MMR: mismatch repair; FA: fanconi anemia pathway. 
 
4.2 DDR defects in mCRPC 
An enrichment of DDR gene alterations can be found during PCa progression, 
especially when the disease develops into metastatic CRPC (mCRPC) (summarized in 
Table 3) (54-56). Heavily pre-treated mCRPC contained more genetic alterations in 
DDR genes (46%) than treatment-naive high grade localized tumors (27%) (54). A 
multi-institutional clinical sequencing study revealed that the majority of affected 
individuals with CRPC harbor clinically actionable homozygous molecular alterations, 
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with 23% of mCRPC harboring DDR aberrations and 8% harboring DDR germline 
mutations (55). Aberrations in BRCA1, BRCA2 and ATM were observed at substantially 
higher frequencies (19.3% overall) in mCRPC compared to those in primary PCa. 
Among these DDR alterations, BRCA2 was the most frequently altered (12.7%), and 
∼90% of these BRCA2 defective tumors exhibited biallelic loss. As aberrations in these 
genes are expected to confer sensitivity to PARP inhibitors (56), nearly 20% of mCRPC 
patients may potentially benefit from this therapy. Additionally, three out of four 
mCRPC tumors in this cohort which presented hypermutations are harboring defects in 
the MMR pathway genes MLH1 or MSH2 (55). Whether this abundance of DDR 
alterations is specifically targeted to these genes or a general consequence of high 
mutational burden for advanced disease is still unclear.  
Table 3 Prevalence of selected DDR genes alteration in mCRPC 
 DDR pathway 
involved 
Grasso et al 
(54) 
Robinson et al (55) Total 
Patients (n)  59 150 209 
ATM General 11.8% (7) 5.3% (8) 7.2% (15) 
ATR 5% (3) 8.6% (13) 7.7% (16) 
BRCA1  
HR 
 0.7% (1) 0.5% (1) 
BRCA2 11.8% (7) 9.3% (14) 10.0% (21) 
RAD51 1.7% (1) 2.0% (3) 1.9% (4) 
PARP1 BER 3% (2) 2.7% (4) 5.5% (6) 
MLH1 MMR 1.7% (1) 1.3% (2) 1.4% (3) 
MSH2 3.3% (2) 2.7% (4) 2.9% (6) 
FANCD2 FA 3.3% (2) 2.7% (4) 2.9% (6) 
All genes  41.6% 35.3% 40% 
Data was acquired from The Memorial Sloan Kettering cBioportal database (http://cbioportal.org). 
ATM: Ataxia–telangiectasia mutated serine/threonine kinase; ATR: ATM and RAD3-related 
serine/threonine kinase; BRCA1/2: Breast Cancer 1 and 2; RAD51: RAD51 recombinase; PARP1: 
poly(ADP-ribose) polymerase 1; MLH1: MutL homolog 1; MSH2: MutS protein homolog 2; 
FANCD2: FA complementation group D2. HR: homologous recombination; BER: base excision 
repair; MMR: mismatch repair; FA: fanconi anemia pathway  
 
4.3 DDR defects and response to PCa treatment 
Various retrospective and prospective studies have been performed in which treatment 
outcome to conventional PCa treatment was compared in DDR mutation carriers and 
wild type individuals. The prognostic and predictive impact related to standard 
therapies for DDR mutated mCRPC has yet to be determined, since these trials 
(summarized in Table 4) report inconsistent and conflicting outcomes: one study found 
no difference between the patient groups (57), while other studies reported DDR 
mutation carriers to have either inferior (58) or improved responses (59, 60) to the 
 
 
therapy. This inconsistency could be explained in several ways. First, the number of 
mCRPC patients harboring DDR mutations is very limited in each cohort. Second, the 
results can be biased due to different sampling, as metastatic biopsies are only feasible 
for patients with low-to-moderate tumor burden. This might exclude highly aggressive 
tumors and blood-based sequencing may underestimate the mutation rate as the somatic 
status is unknown for certain patients. Third, the disease showed extensive 
heterogeneity and patients had received various pre-treatments in the different cohorts. 
A recent prospective study showed that BRCA2 mutation carriers have a worse outcome 
in mCRPC disease and this may be affected by the first line treatment used (61). 
However, future prospective studies are needed to shed further light on this issue and 
will hopefully resolve the above-mentioned controversy. 
Table 4 Clinical outcome of mCRPC patients with wild type vs DDR gene mutations after 
standard AR targeting therapy  
Author 
and year 
Study 
design 
Sampling Treatment  DDR defect 
patients 
PSA-PFS OS 
Annala et 
al 
2017 (58) 
Retrospective 
Four cohorts  
Blood 
Germline 
 
Enzalutamide 
Abiraterone 
24/319 (7.5%) 
 
3.3 mo DDR (-) 
vs 6.2 mo WT 
29.7 mo DDR (-) 
 vs 34.1 mo WT 
Mateo et al 
2018 (57) 
Retrospective 
 Two cohorts 
Blood 
Germline 
Enzalutamide/ 
Abiraterone 
60/390 (15.4%) 8.3 mo DDR 
(-), vs 8.3 mo 
WT 
36 mo DDR (-) vs 
38.4 mo WT 
Antonarak
is et al 
2018 (59) 
Retrospective
/ prospective 
Single cohort 
Blood 
Germline 
Enzalutamide/ 
Abiraterone 
22/172 (12%) 10.2 mo DDR 
(-) vs 7.6 mo 
WT 
41.1 mo DDR (-) 
vs 28.3 mo WT 
Hussain et 
al 
2018 (60) 
Randomized 
phase II 
multicenter 
trial 
Biopsy 
Mixed 
Abiraterone 
plus Prednisone 
20/80 (25%) 16.6 mo DDR 
(-) vs 8.2 mo 
WT 
N/A 
Castro et 
al 
2019 (61) 
Prospective  
multicenter 
\cohort 
Blood  
Germline  
Abiraterone 
Enzalutamide  
16/302 (5.3%) 
8/126 (6.3%) 
8.1 mo DDR (-) 
Vs 9.2 mo WT 
(combined) 
N/A 
PSA: prostate specific antigen; PFS: progression-free survival; OS: overall survival; DDR: DNA 
damage response; WT: wild-type. 
 
5. AR and DDR pathway crosstalk 
Clinical trials have shown that the combination of ADT or anti-androgens with 
radiotherapy significantly increases patient survival and reduces distant metastases 
compared to radiotherapy alone (64-69). It is widely perceived that suppression of the 
AR axis enhances the cytotoxic effects of radiotherapy and based on the beneficial 
effects, this combination is currently the standard of care for locally advanced PCa.  
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with 23% of mCRPC harboring DDR aberrations and 8% harboring DDR germline 
mutations (55). Aberrations in BRCA1, BRCA2 and ATM were observed at substantially 
higher frequencies (19.3% overall) in mCRPC compared to those in primary PCa. 
Among these DDR alterations, BRCA2 was the most frequently altered (12.7%), and 
∼90% of these BRCA2 defective tumors exhibited biallelic loss. As aberrations in these 
genes are expected to confer sensitivity to PARP inhibitors (56), nearly 20% of mCRPC 
patients may potentially benefit from this therapy. Additionally, three out of four 
mCRPC tumors in this cohort which presented hypermutations are harboring defects in 
the MMR pathway genes MLH1 or MSH2 (55). Whether this abundance of DDR 
alterations is specifically targeted to these genes or a general consequence of high 
mutational burden for advanced disease is still unclear.  
Table 3 Prevalence of selected DDR genes alteration in mCRPC 
 DDR pathway 
involved 
Grasso et al 
(54) 
Robinson et al (55) Total 
Patients (n)  59 150 209 
ATM General 11.8% (7) 5.3% (8) 7.2% (15) 
ATR 5% (3) 8.6% (13) 7.7% (16) 
BRCA1  
HR 
 0.7% (1) 0.5% (1) 
BRCA2 11.8% (7) 9.3% (14) 10.0% (21) 
RAD51 1.7% (1) 2.0% (3) 1.9% (4) 
PARP1 BER 3% (2) 2.7% (4) 5.5% (6) 
MLH1 MMR 1.7% (1) 1.3% (2) 1.4% (3) 
MSH2 3.3% (2) 2.7% (4) 2.9% (6) 
FANCD2 FA 3.3% (2) 2.7% (4) 2.9% (6) 
All genes  41.6% 35.3% 40% 
Data was acquired from The Memorial Sloan Kettering cBioportal database (http://cbioportal.org). 
ATM: Ataxia–telangiectasia mutated serine/threonine kinase; ATR: ATM and RAD3-related 
serine/threonine kinase; BRCA1/2: Breast Cancer 1 and 2; RAD51: RAD51 recombinase; PARP1: 
poly(ADP-ribose) polymerase 1; MLH1: MutL homolog 1; MSH2: MutS protein homolog 2; 
FANCD2: FA complementation group D2. HR: homologous recombination; BER: base excision 
repair; MMR: mismatch repair; FA: fanconi anemia pathway  
 
4.3 DDR defects and response to PCa treatment 
Various retrospective and prospective studies have been performed in which treatment 
outcome to conventional PCa treatment was compared in DDR mutation carriers and 
wild type individuals. The prognostic and predictive impact related to standard 
therapies for DDR mutated mCRPC has yet to be determined, since these trials 
(summarized in Table 4) report inconsistent and conflicting outcomes: one study found 
no difference between the patient groups (57), while other studies reported DDR 
mutation carriers to have either inferior (58) or improved responses (59, 60) to the 
 
 
therapy. This inconsistency could be explained in several ways. First, the number of 
mCRPC patients harboring DDR mutations is very limited in each cohort. Second, the 
results can be biased due to different sampling, as metastatic biopsies are only feasible 
for patients with low-to-moderate tumor burden. This might exclude highly aggressive 
tumors and blood-based sequencing may underestimate the mutation rate as the somatic 
status is unknown for certain patients. Third, the disease showed extensive 
heterogeneity and patients had received various pre-treatments in the different cohorts. 
A recent prospective study showed that BRCA2 mutation carriers have a worse outcome 
in mCRPC disease and this may be affected by the first line treatment used (61). 
However, future prospective studies are needed to shed further light on this issue and 
will hopefully resolve the above-mentioned controversy. 
Table 4 Clinical outcome of mCRPC patients with wild type vs DDR gene mutations after 
standard AR targeting therapy  
Author 
and year 
Study 
design 
Sampling Treatment  DDR defect 
patients 
PSA-PFS OS 
Annala et 
al 
2017 (58) 
Retrospective 
Four cohorts  
Blood 
Germline 
 
Enzalutamide 
Abiraterone 
24/319 (7.5%) 
 
3.3 mo DDR (-) 
vs 6.2 mo WT 
29.7 mo DDR (-) 
 vs 34.1 mo WT 
Mateo et al 
2018 (57) 
Retrospective 
 Two cohorts 
Blood 
Germline 
Enzalutamide/ 
Abiraterone 
60/390 (15.4%) 8.3 mo DDR 
(-), vs 8.3 mo 
WT 
36 mo DDR (-) vs 
38.4 mo WT 
Antonarak
is et al 
2018 (59) 
Retrospective
/ prospective 
Single cohort 
Blood 
Germline 
Enzalutamide/ 
Abiraterone 
22/172 (12%) 10.2 mo DDR 
(-) vs 7.6 mo 
WT 
41.1 mo DDR (-) 
vs 28.3 mo WT 
Hussain et 
al 
2018 (60) 
Randomized 
phase II 
multicenter 
trial 
Biopsy 
Mixed 
Abiraterone 
plus Prednisone 
20/80 (25%) 16.6 mo DDR 
(-) vs 8.2 mo 
WT 
N/A 
Castro et 
al 
2019 (61) 
Prospective  
multicenter 
\cohort 
Blood  
Germline  
Abiraterone 
Enzalutamide  
16/302 (5.3%) 
8/126 (6.3%) 
8.1 mo DDR (-) 
Vs 9.2 mo WT 
(combined) 
N/A 
PSA: prostate specific antigen; PFS: progression-free survival; OS: overall survival; DDR: DNA 
damage response; WT: wild-type. 
 
5. AR and DDR pathway crosstalk 
Clinical trials have shown that the combination of ADT or anti-androgens with 
radiotherapy significantly increases patient survival and reduces distant metastases 
compared to radiotherapy alone (64-69). It is widely perceived that suppression of the 
AR axis enhances the cytotoxic effects of radiotherapy and based on the beneficial 
effects, this combination is currently the standard of care for locally advanced PCa.  
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The molecular mechanism of radiosensitization induced by ADT was investigated 
in preclinical studies. Goodwin et al. reported that ADT potentiates the tumor-killing 
effect of ionizing radiation (IR) in AR proficient cells both in vitro and in vivo: ADT 
treated C4-2 (androgen independent) cells had a diminished capacity to repair IR 
induced DSBs. This study showed that the AR pathway directly regulates the NHEJ 
factor DNA-dependent protein kinase catalytic subunit (DNA-PKcs), resulting in a 
slight increase in NHEJ activity upon androgen addition in a plasmid-based functional 
assay (12). The involvement of NHEJ was confirmed by Polkinghorn et al. who 
identified a set of 32 DDR genes as direct AR target genes (70). Other studies using 
patient samples have demonstrated that castration primarily reduces Ku70 protein 
expression, which is essential for NHEJ (71, 72). These studies suggest that ADT 
enhances IR effects by impairing NHEJ activity. Reciprocally, IR treatment caused 
marked induction of the androgen target genes TMPRSS2 and FKBP5 (12), suggesting 
that DNA damage induces AR activity (Figure 2).  
 
Figure 2. Interplay between androgen receptor (AR) and DNA damage repair in prostate 
cancer.  
Activation of AR by dihydrotestosterone (T) leads to transcriptional upregulation of DNA repair 
genes in various repair pathways. Reciprocally, irradiation result in upregulation of keys genes in 
the AR pathway via ROS. HR, homologous recombination; NHEJ, non-homologous end-joining; 
ROS, reactive oxygen species; IR: irradiation. 
 
In addition to direct regulation of the NHEJ pathway, other studies show that AR 
signaling plays a role in regulating genes involved in the HR, MMR and FA pathways 
 
 
(12, 70, 73). Enzalutamide treatment suppressed the expression of the HR genes BRCA1, 
RAD54L and RecQ Mediated Genome Instability 2 (RMI2) (73). A combination 
strategy in which enzalutamide pretreatment was followed by the PARP inhibitor 
olaparib resulted in significantly increased PCa cell apoptosis and inhibited colony 
formation in vitro. Further in vivo evaluation showed clear synergistic suppressive 
effects on PCa xenografts in hormone-sensitive models, but not in CRPC models (73). 
However, from these studies, it is not yet clear whether enzalutamide directly induces 
HR deficiency, also called the BRCAness phenotype. A reduction of the S/G2 cell cycle 
fraction might also have caused reduction of HR gene expression, which resulted in 
reduced HR in the total cell population. Whatever the mechanistic explanation may be, 
this study warrants further clinical investigation into AR and PARP inhibitor 
combination therapies. 
Based on these results, it is clear that both preclinical and clinical studies have 
found that AR signaling regulates the expression and/or function of DDR genes. 
Elucidation of the precise regulatory mechanisms and pathway interactions requires 
additional studies, which should focus on direct measurement of NHEJ and HR capacity 
in the presence and absence of AR signaling. 
6. Exploiting DDR alterations for PCa treatment  
As discussed above, 10-25% of PCa patients are harboring DDR mutations, especially 
among mCRPC patients. This section summarizes clinical and preclinical evidence how 
DDR alterations could be exploited therapeutically. 
6.1 Immune checkpoint inhibitors 
The successful development of immune checkpoint inhibitors such as programmed cell 
death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors 
revolutionized the field of cancer immunotherapy (74). The interaction of PD-L1 on 
tumor cells with PD-1 on T-cells reduces T-cell functionality, preventing the immune 
system from attacking the tumor cells. Inhibitors that block this interaction can unleash 
a patient’s own T cells to kill tumors (75). Immunotherapy responses appear to correlate 
with the mutational burden, presumably by the increase in neo-antigens (76). PCa 
patients harboring MMR mutations, such as in MLH1 or MSH2, could be selected for 
PD-1 blockade immunotherapy, as a favorable response to PD-1 blockade therapy was 
observed previously in MMR deficient tumors, as a result of the high level of neo-
antigens in various solid tumors (77). Interestingly, ductal adenocarcinoma, an 
aggressive histopathology of PCa, is associated with MMR defects, suggesting that 
these patients are possible candidates for this type of immunotherapy (78). Interestingly, 
an increase in neo-antigens was also observed in patients who harbor a HR deficiency 
(79). Altogether, these subgroups represent nearly 20% of mCRPC patients, making the 
use of PD-1/PD-L1 inhibitors a potentially attractive strategy for clinical trials in these 
patients. 
6.2 PARP inhibitor treatments 
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The molecular mechanism of radiosensitization induced by ADT was investigated 
in preclinical studies. Goodwin et al. reported that ADT potentiates the tumor-killing 
effect of ionizing radiation (IR) in AR proficient cells both in vitro and in vivo: ADT 
treated C4-2 (androgen independent) cells had a diminished capacity to repair IR 
induced DSBs. This study showed that the AR pathway directly regulates the NHEJ 
factor DNA-dependent protein kinase catalytic subunit (DNA-PKcs), resulting in a 
slight increase in NHEJ activity upon androgen addition in a plasmid-based functional 
assay (12). The involvement of NHEJ was confirmed by Polkinghorn et al. who 
identified a set of 32 DDR genes as direct AR target genes (70). Other studies using 
patient samples have demonstrated that castration primarily reduces Ku70 protein 
expression, which is essential for NHEJ (71, 72). These studies suggest that ADT 
enhances IR effects by impairing NHEJ activity. Reciprocally, IR treatment caused 
marked induction of the androgen target genes TMPRSS2 and FKBP5 (12), suggesting 
that DNA damage induces AR activity (Figure 2).  
 
Figure 2. Interplay between androgen receptor (AR) and DNA damage repair in prostate 
cancer.  
Activation of AR by dihydrotestosterone (T) leads to transcriptional upregulation of DNA repair 
genes in various repair pathways. Reciprocally, irradiation result in upregulation of keys genes in 
the AR pathway via ROS. HR, homologous recombination; NHEJ, non-homologous end-joining; 
ROS, reactive oxygen species; IR: irradiation. 
 
In addition to direct regulation of the NHEJ pathway, other studies show that AR 
signaling plays a role in regulating genes involved in the HR, MMR and FA pathways 
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RAD54L and RecQ Mediated Genome Instability 2 (RMI2) (73). A combination 
strategy in which enzalutamide pretreatment was followed by the PARP inhibitor 
olaparib resulted in significantly increased PCa cell apoptosis and inhibited colony 
formation in vitro. Further in vivo evaluation showed clear synergistic suppressive 
effects on PCa xenografts in hormone-sensitive models, but not in CRPC models (73). 
However, from these studies, it is not yet clear whether enzalutamide directly induces 
HR deficiency, also called the BRCAness phenotype. A reduction of the S/G2 cell cycle 
fraction might also have caused reduction of HR gene expression, which resulted in 
reduced HR in the total cell population. Whatever the mechanistic explanation may be, 
this study warrants further clinical investigation into AR and PARP inhibitor 
combination therapies. 
Based on these results, it is clear that both preclinical and clinical studies have 
found that AR signaling regulates the expression and/or function of DDR genes. 
Elucidation of the precise regulatory mechanisms and pathway interactions requires 
additional studies, which should focus on direct measurement of NHEJ and HR capacity 
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patients harboring MMR mutations, such as in MLH1 or MSH2, could be selected for 
PD-1 blockade immunotherapy, as a favorable response to PD-1 blockade therapy was 
observed previously in MMR deficient tumors, as a result of the high level of neo-
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aggressive histopathology of PCa, is associated with MMR defects, suggesting that 
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an increase in neo-antigens was also observed in patients who harbor a HR deficiency 
(79). Altogether, these subgroups represent nearly 20% of mCRPC patients, making the 
use of PD-1/PD-L1 inhibitors a potentially attractive strategy for clinical trials in these 
patients. 
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Monotherapy 
Tumors with compromised HR are highly sensitive to reduction of SSB repair by 
PARP1 inhibition, a phenomenon called synthetic lethality (80-82). The mechanism of 
action of PARP inhibitors was originally described as inhibition of SSB repair via 
blocking the catalytic activity of PARP1. Unrepaired SSBs will be converted into the 
more genotoxic DSBs during DNA replication. These DSBs are repaired via HR in 
normal cells, but cannot be repaired in HR-deficient cancer cells, leading to tumor-
specific cell death. Recently, this model has been updated as studies have shown that 
various PARP inhibitors are able to trap PARP1 at the DNA damage site (83-85). 
Trapped PARP results in DSBs when the replication fork encounters this lesion, which 
require HR for resolution (Figure 3). Considering the different PARP trapping abilities 
of the different PARP inhibitors, various therapeutic responses can be expected, with 
talazoparib having the most profound PARP trapping and cytotoxic effects (86). 
Following previous in vitro (80, 81) and in vivo studies in Brca2 knockout breast 
and ovarian tumor mouse models (87, 88), a number of trials evaluated PARP inhibitors 
as a single agent in CRPC patients with HR defects. The TOPARP study evaluated 
olaparib in a population of 50 mCRPC patients. Interestingly, 14 out of 16 DDR 
mutation carriers responded to olaparib treatment, compared to 2 of 33 patients in the 
non-DDR mutated group (56). The promising results from this study led to the initiation 
of a large number of clinical trials targeting PARP by different inhibitors with or 
without HR gene mutation preselection in order to validate the effect, evaluate its safety 
profile and define the optimal timing of prescribing PARP inhibitors in mCRPC (89-
92). Interestingly, a recently published multicenter retrospective study including 23 
mCRPC patients harboring DDR mutations (2 BRCA1, 15 BRCA2 an 6 ATM) showed 
that men with ATM mutations responded inferior to PARP inhibitor treatment compared 
to BRCA1/2 mutation carriers (93). These data suggest that ATM mutated patients may 
not benefit from PARP inhibitor treatment as previously thought, and preselection of 
patients is importance to avoid unnecessary toxicity. 
 It is to be expected that due to increased use of next generation sequencing 
approaches, it is likely that more PCa patients with HR defects will be detected. 
However, the implementation and standardization of genomic testing still remains a 
major challenge. Besides blood based germline mutation and biopsy based somatic 
mutation testing, new studies are looking into circulating tumor cells (CTC) or cell-free 
DNA based detection of a panel of clinically actionable genes to select eligible patients 
(90, 94, 95). Moreover, the efforts made for identifying tumors with HR deficiency by 
using mutational signatures (HRDetect) or functional HRD tests will guide us to a more 
personalized cancer management approach (96-100). 
 
 
 
Figure 3. Mechanism of action of Poly(ADP-ribose) polymerase (PARP) inhibitor.  
PARP enhances repair of single-strand breaks (SSBs) via base excision repair (BER). If SSBs 
remain unrepaired due to inhibition of PARP catalytic activity with PARP inhibitors (PARPi), 
double-strand breaks (DSBs) can be formed during replication. Alternatively, PARPi can trap the 
PARP protein on the DNA, which causes replication fork (RF) stalling and collapse. Homologous 
recombination (HR) is essential for repairing these DSBs. 
 
Combination therapies 
Besides PARP inhibition as monotherapy, trials have been initiated to evaluate 
combination of PARP inhibitors with other treatments in mCRPC patients. In view of 
the working mechanism of PARP inhibitors, an obvious strategy is to combine them 
with DNA-damaging agents, such as chemotherapy, radiotherapy and radioligand 
therapy (ongoing clinical trials are summarized in Table 5). Synergy with PARP 
inhibitors was identified in various clinical trials in other tumor types (101). However 
overlapping hematological toxicities may represent a major hurdle when combining 
DNA-damaging agents and PARP inhibitors (102). 
Previous preclinical work offered the rationale for the potential synergy of 
combining AR-targeting agents with PARP inhibitors. First, blockage of AR signaling 
and PARP inhibition cause downregulation of the DNA repair capacity of the cells via 
different complementary pathways (DSB repair and SSB repair) (73, 103). According 
to preclinical studies, anti-androgen treatments may induce a BRCAness phenotype, 
which can be targeted by PARP inhibition. Second, PARP1 has been reported to 
promote AR-dependent transcription and PARP inhibitors will therefore reduce AR-
functioning (104). Unfortunately, a randomized multicenter trial failed to show a 
significant difference in prostate-specific antigen (PSA) response rate and median 
progression-free survival (PFS) between patients treated with abiraterone/prednisone 
plus the PARP inhibitor veliparib compared to abiraterone/prednisone alone (105). 
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Combination therapies 
Besides PARP inhibition as monotherapy, trials have been initiated to evaluate 
combination of PARP inhibitors with other treatments in mCRPC patients. In view of 
the working mechanism of PARP inhibitors, an obvious strategy is to combine them 
with DNA-damaging agents, such as chemotherapy, radiotherapy and radioligand 
therapy (ongoing clinical trials are summarized in Table 5). Synergy with PARP 
inhibitors was identified in various clinical trials in other tumor types (101). However 
overlapping hematological toxicities may represent a major hurdle when combining 
DNA-damaging agents and PARP inhibitors (102). 
Previous preclinical work offered the rationale for the potential synergy of 
combining AR-targeting agents with PARP inhibitors. First, blockage of AR signaling 
and PARP inhibition cause downregulation of the DNA repair capacity of the cells via 
different complementary pathways (DSB repair and SSB repair) (73, 103). According 
to preclinical studies, anti-androgen treatments may induce a BRCAness phenotype, 
which can be targeted by PARP inhibition. Second, PARP1 has been reported to 
promote AR-dependent transcription and PARP inhibitors will therefore reduce AR-
functioning (104). Unfortunately, a randomized multicenter trial failed to show a 
significant difference in prostate-specific antigen (PSA) response rate and median 
progression-free survival (PFS) between patients treated with abiraterone/prednisone 
plus the PARP inhibitor veliparib compared to abiraterone/prednisone alone (105). 
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Lack of effectivity can be explained by inefficient PARP trapping by veliparib. 
Interestingly, another recent randomized double-blind phase 2 trial showed 
significantly longer PFS for mCRPC patients receiving olaparib plus abiraterone 
treatment than single abiraterone therapy. Although the combination strategy showed 
more adverse events than monotherapy, the health-related quality of life did not decline 
(106). These clinical data support the preclinical results in which synergy between 
olaparib and AR signaling inhibitor was found, regardless of the HR status (73, 103). 
Other trials are combining PARP inhibitors with vascular endothelial growth factor 
(VEGF) inhibitors, which function by inhibiting tumor angiogenesis. Preclinical studies 
showed that restriction of angiogenesis induces hypoxia, which may create a 
BRCAness phenotype by reducing the expression of BRCA1 and RAD51 (107). The 
VEGF inhibitors bevacizumab and cediranib were reported to induce severe hypoxia, 
causing a reduction of HR capacity and increased sensitivity to PARP inhibitors (108). 
Based on these data, a clinical study targeting both processes in mCRPC patients is 
ongoing (Table 5). 
Another approach that has been explored is the use of PARP inhibitors as 
radiosensitizer for patients with high-risk localized PCa (radiotherapy) or with 
metastatic lesions (radioligand therapy). Irradiation induces cell death by the production 
of reactive oxygen species (ROS) as well as by direct ionization of the DNA which 
leads to SSBs and DSBs. PARP inhibition is predicted to enhance this effect by 
preventing the repair of radiation-induced SSBs. In vitro models support the idea that 
PARP inhibitors can enhance radiation-induced cytotoxicity (109, 110). Similar results 
were also found in targeted radioligand therapy for PCa (111), suggesting targeted 
radiotherapy can be further optimized in combination with PARP inhibitors. As 
described above, the MMR pathway has been implicated in the immunotherapy 
response and alterations in other DDR genes may also increase efficacy of 
immunotherapy (79, 112). Therefore, several studies were started in which PARP 
inhibitors were combined with immunotherapy. The PARP1 inhibitor talazoparib has 
been found to exhibit immunoregulatory effects in a Brca1 deficient ovarian cancer 
mouse model as the number of peritoneal CD8 (+) T cells and NK cells increased 
significantly after talazoparib treatment (113). Furthermore, Higuchi et al. have shown 
that cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody synergized with PARP 
inhibitors therapeutically in the Brca1 deficient ovarian cancer mouse model and 
support the clinical testing of this combination regimen (114). The first clinical trial 
with a small cohort of patients showed that the PD-L1 inhibitor durvalumab plus 
olaparib in mCRPC patients has acceptable toxicity and efficacy, and the therapeutic 
response is superior in men with DDR abnormalities (115). This triggered other studies 
to investigate whether mCRPC patients with DDR defects would benefit from this 
particular combination therapy. Clinical trials are ongoing to evaluate its safety, optimal 
dosing and efficacy (Table 5).  
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Lack of effectivity can be explained by inefficient PARP trapping by veliparib. 
Interestingly, another recent randomized double-blind phase 2 trial showed 
significantly longer PFS for mCRPC patients receiving olaparib plus abiraterone 
treatment than single abiraterone therapy. Although the combination strategy showed 
more adverse events than monotherapy, the health-related quality of life did not decline 
(106). These clinical data support the preclinical results in which synergy between 
olaparib and AR signaling inhibitor was found, regardless of the HR status (73, 103). 
Other trials are combining PARP inhibitors with vascular endothelial growth factor 
(VEGF) inhibitors, which function by inhibiting tumor angiogenesis. Preclinical studies 
showed that restriction of angiogenesis induces hypoxia, which may create a 
BRCAness phenotype by reducing the expression of BRCA1 and RAD51 (107). The 
VEGF inhibitors bevacizumab and cediranib were reported to induce severe hypoxia, 
causing a reduction of HR capacity and increased sensitivity to PARP inhibitors (108). 
Based on these data, a clinical study targeting both processes in mCRPC patients is 
ongoing (Table 5). 
Another approach that has been explored is the use of PARP inhibitors as 
radiosensitizer for patients with high-risk localized PCa (radiotherapy) or with 
metastatic lesions (radioligand therapy). Irradiation induces cell death by the production 
of reactive oxygen species (ROS) as well as by direct ionization of the DNA which 
leads to SSBs and DSBs. PARP inhibition is predicted to enhance this effect by 
preventing the repair of radiation-induced SSBs. In vitro models support the idea that 
PARP inhibitors can enhance radiation-induced cytotoxicity (109, 110). Similar results 
were also found in targeted radioligand therapy for PCa (111), suggesting targeted 
radiotherapy can be further optimized in combination with PARP inhibitors. As 
described above, the MMR pathway has been implicated in the immunotherapy 
response and alterations in other DDR genes may also increase efficacy of 
immunotherapy (79, 112). Therefore, several studies were started in which PARP 
inhibitors were combined with immunotherapy. The PARP1 inhibitor talazoparib has 
been found to exhibit immunoregulatory effects in a Brca1 deficient ovarian cancer 
mouse model as the number of peritoneal CD8 (+) T cells and NK cells increased 
significantly after talazoparib treatment (113). Furthermore, Higuchi et al. have shown 
that cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody synergized with PARP 
inhibitors therapeutically in the Brca1 deficient ovarian cancer mouse model and 
support the clinical testing of this combination regimen (114). The first clinical trial 
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6.3 Platinum-based chemotherapy  
Platinum-based agents cause crosslinking of DNA, most notably interstrand crosslinks 
that covalently couple both DNA strands (116). These crosslinks interfere with DNA 
replication and translation and induce apoptosis. Although platinum compounds have 
long been studied in advanced PCa patients in a large number of clinical trials, the 
various treatment regimens have not demonstrated a significant overall survival benefit 
in the overall patient population, and no treatment has received approval. Tumors with 
mutations in BRCA1/2 are specifically susceptible to platinum-based chemotherapy 
since the interstrand crosslinks can only be adequately repaired by HR-based DNA 
repair. Recent clinical trials provided evidence that breast and ovarian cancer patients 
with BRCA1/2 mutations are highly sensitive to platinum-based chemotherapy (99, 117, 
118). Pomerantz et al. retrospectively analyzed a single-institution cohort of mCRPC 
patients who received carboplatin-based chemotherapy and showed that BRCA2 
mutation carriers had a higher response rate to carboplatin-based chemotherapy than 
non-BRCA2 associated patients (119). Furthermore, a few case reports also highlighted 
exceptional responses to platinum-treatment in mCRPC patients with HR defects (120, 
121). With such promising results, more trials of carboplatin alone and in combination 
with docetaxel have been designed in advanced PCa harboring DDR aberrations 
(ongoing clinical trials are summarized in Table 6). 
Table 6 Ongoing clinical trials with platinum based chemotherapy  
Trial Treatment Subjects Period Design Primary end 
point 
NCT02311764C Carboplatin mCRPC 
with PTEN 
loss and/or 
DDR 
defect 
February 
2015 - 
April 
2019 
A Single Arm 
Open Label 
Phase II Pilot 
Study 
PSA Response 
NCT02598895 Docetaxel 
+ 
Carboplatin 
mCRPC 
with 
BRCA1/2 
inactivation  
January 
2016 – 
June 2018 
Pilot and 
single group 
assignment 
study 
PSA Response 
NCT02985021 Docetaxel 
+ 
Carboplatin 
mCRPC 
with 
BRCA1/2，
ATM 
inactivation  
November 
2016 -
November 
2019 
A phase 2 
study Single 
Group 
Assignment，
Open label 
PSA response 
mCRPC: metastatic castration resistant prostate cancer; PSA: prostate specific antigen: PTEN: 
phosphatase and tensin homolog; ATM: Ataxia–telangiectasia mutated serine/threonine kinase; 
BRCA1/2: Breast Cancer 1 and 2 
 
6.4 DNA-PKcs targeting treatment  
Besides the discovery of the AR-DDR crosstalk via the key mediator DNA-PKcs, a 
following study has identified a new function of DNA-PKcs as a potent driver of PCa 
progression. Goodwin et al. found that DNA-PKcs functions as a selective modulator 
of transcriptional networks that induce cell migration, invasion and metastasis and 
suppression of DNA-PKcs inhibits tumor metastases. Moreover, DNA-PKcs levels are 
significantly increased in advanced disease and can be independently predictive for 
biochemical recurrence, poor overall survival (122). Based on these findings, a phase I 
 
 
clinical trial is ongoing (NCT02833883) in which the combination of enzalutamide and 
DNA-PKcs inhibitor CC-115 is evaluated for treatment of mCRPC. 
 
7.  Conclusion  
The identification of DDR defects in mCRPC has driven the interest for further 
evaluation of these gene deficiencies in patient stratification. PARP inhibitors may 
become part of the standard care of mCRPC patients who harbor HR deficiency; 
however, the most optimal use of PARP inhibitors alone or in combination with other 
treatment modalities remains to be elucidated. Given the clearly aggressive course of 
DDR-deficient PCa, there is an urgent need to identify these patients at an early stage 
where the right treatment strategy could greatly improve prognosis. The discovery that 
the AR may regulate DDR factors opens a new array of possible strategies to optimize 
treatment combinations. Future studies are needed to broaden our understanding of 
DDR defects and interactions between DNA repair pathways and other processes in 
PCa, as well as to determine how this knowledge can be used to improve diagnostic, 
prognostic and therapeutic approaches. 
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Abstract  
Background  
In vitro models of prostate cancer (PCa) are not always reliable to evaluate anticancer 
treatment efficacy. This limitation may be overcome by using viable organotypic tumor 
slice material. Here we report on the establishment of an ex vivo method to culture tissue 
slices from patient-derived xenografts (PDX) of PCa, to assess responses to PCa 
treatments. 
Methods 
Three PDX models were used that are characterized by different androgen receptor (AR) 
expression and different homology directed DNA repair capacities, due to a breast 
cancer associated 2 (BRCA2) wild type or mutated status. Tumors were removed from 
mice, sliced using a vibratome and cultured for a maximum of 6 days. To test the 
sensitivity to androgen antagonist, tumor slices from the AR-expressing and AR-
negative PDX tumors were treated with the anti-androgen enzalutamide. For sensitivity 
to DNA repair intervention, tumors slices from BRCA2 wild type and mutated PDXs 
were treated with the poly (ADP-ribose) polymerase-1 inhibitor olaparib. Treatment 
response in these tumor slices was determined by measuring slice morphology, cell 
proliferation, apoptosis, AR expression level and secretion of prostate specific antigen 
(PSA). 
Results 
We compared various culture conditions (support materials, growth media and use of a 
3D smooth rocking platform) to find the optimal condition to maintain tissue viability 
and proliferative capacity for at least 6 days. Under optimized conditions, enzalutamide 
treatment significantly decreased proliferation, increased apoptosis, and reduced AR-
expression and PSA secretion of AR-expressing tumor slices compared to AR-negative 
slices, that did not respond to the intervention. Olaparib treatment significantly 
increased cell death in BRCA2 mutated tumors slices as compared to slices from BRCA2 
wild type tumors. 
Conclusions 
Ex vivo treatment of PCa PDX tumor slices with enzalutamide and olaparib 
recapitulates responses previously observed in vivo. The faithful retention of tissue 
structure and function in this ex vivo model offers an ideal opportunity for treatment 
efficacy screening, thereby reducing costs and numbers of experimental animals. 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Prostate cancer (PCa) is the second most common cancer in men and the fourth most 
common tumor type worldwide (1). PCa remains a high burden in the current healthcare 
system, especially once it develops into castration resistant PCa (CRPC). Although 
therapeutic strategies have improved over the past decades, their gains are often 
transient and only marginally increase survival of CRPC patients. Therefore, there is a 
clear unmet clinical need for better treatment options and predictive markers for CPRC 
patients. Currently, a multitude of novel targets and compounds are in the pipeline for 
testing. In order to speed up the process from development towards clinical use, faster 
and better test models are urgently needed. When developing and testing novel 
therapies, it is essential to have a cancer model that is both reliable and representative. 
Most preclinical studies of PCa depend heavily on immortalized cancer cell lines, 
which are grown in culture dishes as a two-dimensional model. These models do not 
recapitulate the complex architecture of tumors nor the important interaction between 
tumor cells and their microenvironment (2). They do therefore not always accurately 
predict treatment efficacy and these limitations could lead to a failure when 
transitioning a new drug from the bench to the clinic. 
As an alternative, organotypic culture of tumor slices represent a solid model 
system for drug sensitivity testing due to its relatively short generation time and 
reflection of the tumor microenvironment (3-7). For example, several studies have 
shown that breast tumor tissue slices can be used to assess chemotherapy response in 
the context of personalized medicine (8-10). In recent years, efforts have been 
undertaken to establish such strategies to generate primary cultures from human 
prostate tumors and innovative complex culture systems. Unfortunately, the 
establishment of primary PCa organotypic cultures proved to be extremely challenging 
due to the slow-growing characteristics of the PCa cells; basal epithelial cells proliferate 
faster than tumor cells and often outgrow them during prolonged culture (11-13). 
To allow testing of therapy responses in different genetics and functional 
background of PCa, we set out to develop an optimized tissue slice culture system. For 
that, we used well-established patient-derived xenograft (PDXs) models as a source for 
the tissue slices (14,15) and show that treatment outcome of these slices recapitulates 
responses previously found in vivo. 
2. Materials and Methods  
2.1 Reagents 
Reagents were purchased from Sigma-Aldrich (Germany) unless otherwise specified. 
2.2 Collection of PDX tumor tissue 
PDXs of PCa (PC295, PC339 and PC310) were established by van Weerden et al. (14) 
and were routinely passaged by subcutaneous grafting of small fragments onto both 
shoulders of intact male athymic NMRI nu/nu mice (Taconic Biosciences, Germany). 
Characteristics of the different PDXs are summarized in Table 1. Fresh PDX tumors 
with volume of 500-1000 mm3 were obtained. After removal from mice, the tumors 
were kept on ice in Dulbecco's Modified Eagle Medium (DMEM; Lonza, Belgium). 
2.3 Tissue slice and culture 
Tumor slices were generated using a vibratome (Leica VT1200S; Leica, Germany) with 
a thickness set at 300 μm, vibration amplitude at 3.0 mm and slicing speed at 0.6 
mm/sec. Slices were either submerged directly in 3 mL culture medium or placed on 
Falcon 40 μm Cell Strainers (Corning, NY, USA) or Millicell 0.4 μm Cell inserts 
(Merck Millipore, Bedford, USA) and then cultured in 3 mL culture medium in 6 well 
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therapeutic strategies have improved over the past decades, their gains are often 
transient and only marginally increase survival of CRPC patients. Therefore, there is a 
clear unmet clinical need for better treatment options and predictive markers for CPRC 
patients. Currently, a multitude of novel targets and compounds are in the pipeline for 
testing. In order to speed up the process from development towards clinical use, faster 
and better test models are urgently needed. When developing and testing novel 
therapies, it is essential to have a cancer model that is both reliable and representative. 
Most preclinical studies of PCa depend heavily on immortalized cancer cell lines, 
which are grown in culture dishes as a two-dimensional model. These models do not 
recapitulate the complex architecture of tumors nor the important interaction between 
tumor cells and their microenvironment (2). They do therefore not always accurately 
predict treatment efficacy and these limitations could lead to a failure when 
transitioning a new drug from the bench to the clinic. 
As an alternative, organotypic culture of tumor slices represent a solid model 
system for drug sensitivity testing due to its relatively short generation time and 
reflection of the tumor microenvironment (3-7). For example, several studies have 
shown that breast tumor tissue slices can be used to assess chemotherapy response in 
the context of personalized medicine (8-10). In recent years, efforts have been 
undertaken to establish such strategies to generate primary cultures from human 
prostate tumors and innovative complex culture systems. Unfortunately, the 
establishment of primary PCa organotypic cultures proved to be extremely challenging 
due to the slow-growing characteristics of the PCa cells; basal epithelial cells proliferate 
faster than tumor cells and often outgrow them during prolonged culture (11-13). 
To allow testing of therapy responses in different genetics and functional 
background of PCa, we set out to develop an optimized tissue slice culture system. For 
that, we used well-established patient-derived xenograft (PDXs) models as a source for 
the tissue slices (14,15) and show that treatment outcome of these slices recapitulates 
responses previously found in vivo. 
2. Materials and Methods  
2.1 Reagents 
Reagents were purchased from Sigma-Aldrich (Germany) unless otherwise specified. 
2.2 Collection of PDX tumor tissue 
PDXs of PCa (PC295, PC339 and PC310) were established by van Weerden et al. (14) 
and were routinely passaged by subcutaneous grafting of small fragments onto both 
shoulders of intact male athymic NMRI nu/nu mice (Taconic Biosciences, Germany). 
Characteristics of the different PDXs are summarized in Table 1. Fresh PDX tumors 
with volume of 500-1000 mm3 were obtained. After removal from mice, the tumors 
were kept on ice in Dulbecco's Modified Eagle Medium (DMEM; Lonza, Belgium). 
2.3 Tissue slice and culture 
Tumor slices were generated using a vibratome (Leica VT1200S; Leica, Germany) with 
a thickness set at 300 μm, vibration amplitude at 3.0 mm and slicing speed at 0.6 
mm/sec. Slices were either submerged directly in 3 mL culture medium or placed on 
Falcon 40 μm Cell Strainers (Corning, NY, USA) or Millicell 0.4 μm Cell inserts 
(Merck Millipore, Bedford, USA) and then cultured in 3 mL culture medium in 6 well 
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plates. The culture media that were tested for quality assessment are summarized in 
Table II. Slices were put in culture within 3 h after the tumor was removed from the 
mouse. Culturing was performed at 5% CO2 at 37°C and at atmospheric oxygen levels. 
Culture plates were standing still or were subjected to movement at 6 rpm using 
Luckham 4RT Rocking Table (Luckham 200 Ltd, West Sussex, UK). One third of 
medium was refreshed and collected daily. Slices were harvested at various time points 
and fixed in 10% neutral buffered formalin for at least 24 h at room temperature (RT). 
Subsequently, tumor slices were embedded in paraffin and 4 μm sections were made 
for further microscopy analysis (for practical setup, see Figure 1). 
2.4 Ex vivo anti-androgen and PARP-1 inhibitor treatment  
To test the response of anti-androgen and poly (ADP-ribose) polymerase-1 (PARP-1) 
inhibitor treatment, tissue slices were cultured under optimal conditions and treated 
with enzalutamide (1 μM, Sequoia Research Products, Pangbourne, UK), olaparib (10 
μM, Selleck Chemicals, Munich, Germany) or with vehicle control (dimethyl sulfoxide, 
DMSO) for different time points. 
2.5 Hematoxylin and eosin staining 
Histological tumor architecture was examined by hematoxylin and eosin (H&E) 
staining. Briefly, sections were deparaffinized in xylene followed by rehydration in 
graded alcohols. They were then stained with hematoxylin for 1 minute, rinsed with tap 
water, stained with eosin for 1 minute, and rinsed again with tap water. The slides were 
then dehydrated with increasing concentration of ethanol successively followed by 
xylene and mounted with entellan. 
2.6 Immunohistochemical and fluorescent procedures 
Sections were deparaffinized in xylene followed by rehydration in graded alcohols. 
Antigen retrieval was performed with target retrieval buffer (Dako, Glostrup, Denmark). 
For diaminobenzidine (DAB) staining, endogenous peroxidase activity was blocked by 
using 3% hydrogen peroxide solution in methanol at RT for 20 min. 5% bovine serum 
albumin (BSA) in phosphate buffered saline (PBS, Lonza, Verviers, Belgium) was used 
to block nonspecific binding. Primary androgen receptor (AR) antibody (M4074, 1/200, 
SPRING Bioscience, CA, USA) and Ki67 antibody (ab16667, 1/200, Abcam, 
Cambridge, UK) diluted in blocking buffer were applied to the sections at 4°C 
overnight. Ki67 was detected with anti-rabbit Alexa Fluor 488 and mounted with 
Vectashield containing DAPI (Vector Laboratories, Burlingame, CA, USA). AR 
staining continues with a horseradish peroxidase (HRP)-conjugated anti-rabbit IgG 
secondary antibody (Dako, Glostrup, Denmark) at a 1:100 dilution for 1 h at RT. AR 
positive cells were visualized using DAB staining kit (Dako, CA, USA) followed by 
counterstaining with hematoxylin. Negative controls were performed for all samples by 
omitting the primary antibodies. 
2.7 EdU incorporation and Click-iT ™ reaction 
5-ethynyl-2'-deoxyuridine (EdU, Invitrogen, USA) at a concentration of 3 μg/mL was 
added to the culture medium 2 h before fixation. For the Click reaction, tissue sections 
were deparaffinized in xylene followed by rehydration in graded alcohols and then 
blocked with PBS containing 1% BSA. After additional washing with PBS, sections 
were incubated with freshly made Click-iT Alexa Fluor 594 cocktail buffer for 30 min 
as previously reported (10). Samples were mounted using Vectashield mounting 
medium with DAPI. 
2.8 TUNEL assay 
 
 
Terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay was 
performed using In Situ Cell Death Detection Kit (Roche Life Sciences, Penzberg, 
Germany) according to instruction of the manufacturer. 
2.9 Medium Prostate-Specific Antigen (PSA) measurement  
Tumor slices culture medium (1 mL) was collected daily for PSA measurement. The 
PSA concentration was measured using a PSA enzyme-linked immunosorbent assay 
(ELISA) kit (Abnova, Taiwan) according to the manufacturer instructions. The 
accumulated PSA concentration in the culture medium was calculated using the 
following formula (which corrects for medium removal each day): 
PSA total (d) = PSA measured (d)*3 +1/3 PSA total (d-1) 
In which d = day of culture. 
2.10 Image acquisition 
AR staining was imaged using a light microscope (Olympus, Tokyo, Japan) and 4 fields 
(200x magnification) from each section were captured. For Ki67, EdU and TUNEL 
staining quantifications, 10 random images (400x magnification) from each tumor slice 
section were generated using a Leica fluorescence microscope (DM4000b, Germany) 
to represent the slice heterogeneity. Representative EdU and TUNEL photos were taken 
by using a Leica SP5 confocal microscope. Image size:512x512 pixels, pixel size 0.7 
μm, 200x magnification (Leica, Germany). 
2.11 Image quantification  
AR expression was quantified by Image J software to yield the pixel ratio of AR 
positive to total nuclei. To quantify the TUNEL microscopy images, all pictures were 
analyzed with the Fraction of overlap with Otsu’s thresholding method: The DAPI and 
the TUNEL image were both thresholded according to Otsu’s algorithm (16) which 
resulted into two binary images. The pixel number was measured and subsequently the 
Mander’s M1 coefficient was used to calculate the fraction of TUNEL positive pixel 
overlapped with DAPI pixel (17). To quantify the fraction of EdU positive cells, the 
fraction of overlap of silhouette images method was used. This method relies on edge 
detection to obtain a binary image. For both the DAPI and EdU pictures, a gradient 
magnitude image was obtained from the image of entry. This binary image was created 
using a modified triangle-thresholding method in which black areas completely 
enclosed by white areas were filled (18). Next, a morphological dilation was applied 
using a circular structuring element with a radius of three pixels. All pixels that still had 
a value of one then constitute a newly formed gradient mask image. The same 
thresholding was applied to the original grayscale image. The intersection of this image 
and all pixels greater than the mean intensity of the original grayscale image formed 
the intensity mask image. A new image was obtained through seeded region growing, 
whereby the gradient mask served as a seed point image and the intensity mask as the 
target image. This newly formed image was subjected to a median filter with a 5x5 
neighborhood and all pixels equal to one constitute the final binary image. Finally, 
Mander’s M1 coefficient was calculated for the fraction of overlap. 
2.12 Statistical analysis  
Results are expressed as the mean ± SEM or median ± quartile in bar graph. Mann–
Whitney test was used to analyze the differences between two groups. Statistical 
analysis and generation of graphs was performed using Graphpad Prism 6.0 (La Jolla, 
CA). P < 0.05 was considered statistically significant. * P < 0.05, ** P < 0.01, *** P < 
0.001 
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3. Results  
3.1 Culture condition selection 
To establish the most optimal method for preservation of PCa tissue slice viability we 
developed a novel culture system and compared it to previously reported systems 
(19,20). Tumor slices from PC295, PC339 and PC310 PCa PDXs were generated using 
a vibratome and these slices were cultured in prostate growth medium (PGM) for 4 days 
under the different conditions in which we compared supporting materials (Figure 1). 
Furthermore, stationary condition and 3D orbital movement on a rocking table were 
compared as smooth 3D orbital movement could increase oxygen and nutrition 
exchange as reported previously (20). H&E stained sections of slices of all three tumors 
showed that slices cultured on cell strainers maintained tissue morphology, while slices 
cultured without support or on inserts lost tissue integrity and showed an increase in 
apoptotic nuclei and vacuolated structures over time (Figure 2A and Figure S1). 
Moreover, in contrast what was observed previously using inserts, we did not observe 
a viability gradient nor loco-regional changes in morphology (15). 
Figure 1. PDX tissue culture methodology. 
The tumor was removed from the mice and sliced with a Leica Vibratome into 300 μm tumor slices. 
Slices were either submerged in culture medium, on Cell Strainers or on Cell Culture inserts. Culture 
dishes were then placed on a Rocking Table or incubated without movement. Slices were harvested 
at various time points and EdU was added 2 h before fixation. Subsequently, fixed tissue was 
embedded in paraffin (FFPE). 
 
The thymidine analogue EdU was used as a real-time proliferation marker to assess 
tissue viability. We tested the reliability of our newly developed EdU quantification 
algorithm by comparing automatic counting with manual counting and a good 
correlation was observed (an R2 of 0.922 and 0.841, respectively for 2 individuals 
compared to automatic counting; Figure S2). A large variability of EdU-positive cells 
was observed between individual image fields and, therefore, 10 fields of view were 
quantified per slice to provide a reliable assessment. Tissue slices cultured on cell 
strainers and under continues 3D orbital movement outperformed the other tissue slice 
methods when looking at maintenance of proliferation at day 4 (Figure 2B and 2C). We 
further evaluated the induction of cell death during ex vivo culturing by TUNEL 
staining, which labels DNA strand breaks generated during apoptosis (21). In line with 
 
 
the results on proliferation, slices cultured on cell strainers did not show an increase in 
apoptosis at 4 days of culture, while slices cultured under the other conditions showed 
enhanced apoptosis. No significant difference in TUNEL signal was observed between 
slices in the stationary condition and those cultured on a rocking table (Figure 2B and 
2D). From these results, we concluded that cell strainer-support and continuous 3D 
orbital movement are optimal for maintenance of tissue slice morphology, proliferation 
and viability. 
 
Figure 2. Effect of filter support and 3D orbital movement on PCa tissue slice morphology 
and viability. 
A) Representative H&E images of PC295 tumor slice sections after 4 days of culturing under the 
different culture conditions, compared to an initial slice (day 0). Scale bar 50 μm. B) Representative 
EdU/TUNEL/DAPI images of PC295 tumor slice sections after 4 days of culturing under the 
different culture conditions, compared to an initial slice (day 0) (blue=DAPI, red=EdU, 
green=TUNEL). Represented H&E and EdU/TUNEL images of PC339 and PC310 tumor slices can 
be found in Figure S1. Scale bar 50 μm. C) Quantification of the fraction of EdU-positive cells in 
the tissue slices. D) Quantification of the fraction of TUNEL positive cells in the tissue slices. For 
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all graphs, 10 image fields were analyzed per tumor slice. Each point represents one image field, 
interquartile range and median values are indicated (results from 1 representative tumor per graph). 
 
3.2  Optimal medium selection 
The culture medium composition has vital impact on the viability of tissue slices. To 
select the optimal medium, we cultured tissue slices in 4 different culture media that 
have been reported previously for primary prostate cell or tumor culturing (Table 2) 
(19,20,22-24). Tissue morphology analysis showed that Prostate Growth Medium 
(PGM) (23) and aDMEM/F12K outperformed the other media tested (Figure S3). 
Table 1. Overview of characteristics of different PDXs. 
PDX Origin1 AD2 AR3 PSA4 BRCA TD 
(days)5 
Pathology type 
PC295 LN + + + WT5 9-11 adenocarcinoma 
PC339 TURP - - - WT 4-7 adenocarcinoma 
PC310 PC + + + HD6 9-11 adenocarcinoma 
1LN = lymph node metastasis, TURP = transurethral resection of the prostate, PC = primary prostate 
tumor; 2AD = androgen dependence (+); 3AR = androgen receptor; 4PSA = prostate specific antigen; 
5WT = wild type; 6HD = homozygous deletion; 5 TD = tumor doubling time 
 
Table 2. Overview of the different medium compositions. 
PGM aDMEM/F12K M199: K-SFM DMEM 
DMEM/Ham’s F12 (1:1) 
BSA (0.01%) 
FCS (2%) 
Epidermal growth factor (10 
ng/mL) 
Insulin-transferrin-selenium (1%) 
Hydrocortison (0.5 µg/mL) 
Triiodothyronine (1 nM) 
Phosphoethanolamine(0.1 mM ) 
Cholera toxin (50 ng/mL) 
Fibronectin (100 ng/mL) 
Fetuine (20 µg/mL) 
R1881 (0.1 nM) 
Penicillin/streptomycin (100 U/mL, 
100 µg/mL) 
PFMR-4A 
(aDMEM/F12K) 
Penicillin/streptomy
cin (100U/mL, 100 
µg/mL) 
M199: K-SFM 
(1:1) 
Antibiotic/antimy
cotic solution 
 
DMEM-high 
glucose 
Penicillin/strepto
mycin 
(100U/mL, 100 
µg/mL)  
 
 
We compared incubation of tissue slices from PC295 and PC339 to determine which 
medium preserved tumor cell viability most optimally. Average tissue proliferation 
remained constant for PC339 (average 10%) up to 6 days of culturing in both media 
while proliferation of PC295 reduced over time in both media (initial 10.7%, and 2.5% 
and 3.6% in PGM and aDMEM/F12K respectively after 6 days). There was no 
significant difference in performance between the two culture media for both PDXs 
(Figure 3A). 
 
 
 
Figure 3. Optimization of culture medium. 
A) Quantification of the fraction of EdU-positive cells of PC295 and PC339 slices cultured up to 6 
days in PGM and aDMEM/F12K medium. B) Quantification of the fraction of EdU-positive cells 
for PC295 and PC339 slices cultured up to 6 days in aDMEM/F12K and aDMEM/F12K 
supplemented with R1881. C) Quantification of the fraction of TUNEL-positive cells for PC295 
and PC339 slices cultured in aDMEM/F12K and aDMEM/F12K supplemented with R1881 at 6 
days. For all graphs, 10 image fields were analyzed per tumor slice section. Each point represents 
one image field, average and SEM are indicated (Three independent experiments for each tumor 
type). ** P < 0.01, *** P < 0.001, ns = non-significant. 
 
PGM constitutes 2% fetal calf serum (FCS) and is supplemented with the synthetic 
androgen R1881 (0.1 nM), while aDMEM/F12K devoid of FCS and does not contain 
R1881. The clear benefit of using serum-free medium led us to test the impact of 
addition of the same concentration of R1881 to the aDMEM/F12K medium. Three 
tumors of PC295 and PC339 each were cultured under optimal conditions in 
aDMEM/F12K or in aDMEM/F12K supplemented with R1881. We found a 
significantly higher proliferation rate of the PC295 slices cultured in aDMEM/F12K 
supplemented with R1881 compared to aDMEM/F12K without R1881 (1.9 folds at day 
6) (Figure 3B). As expected, addition of R1881 did not affect proliferation rates of 
androgen independent PC339 slices (Figure 3B). Some increase in apoptosis was 
observed in PC339, while PC295 maintained its low apoptosis levels for up to 6 days 
of ex vivo culturing (Figure 3C). 
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remained constant for PC339 (average 10%) up to 6 days of culturing in both media 
while proliferation of PC295 reduced over time in both media (initial 10.7%, and 2.5% 
and 3.6% in PGM and aDMEM/F12K respectively after 6 days). There was no 
significant difference in performance between the two culture media for both PDXs 
(Figure 3A). 
 
 
 
Figure 3. Optimization of culture medium. 
A) Quantification of the fraction of EdU-positive cells of PC295 and PC339 slices cultured up to 6 
days in PGM and aDMEM/F12K medium. B) Quantification of the fraction of EdU-positive cells 
for PC295 and PC339 slices cultured up to 6 days in aDMEM/F12K and aDMEM/F12K 
supplemented with R1881. C) Quantification of the fraction of TUNEL-positive cells for PC295 
and PC339 slices cultured in aDMEM/F12K and aDMEM/F12K supplemented with R1881 at 6 
days. For all graphs, 10 image fields were analyzed per tumor slice section. Each point represents 
one image field, average and SEM are indicated (Three independent experiments for each tumor 
type). ** P < 0.01, *** P < 0.001, ns = non-significant. 
 
PGM constitutes 2% fetal calf serum (FCS) and is supplemented with the synthetic 
androgen R1881 (0.1 nM), while aDMEM/F12K devoid of FCS and does not contain 
R1881. The clear benefit of using serum-free medium led us to test the impact of 
addition of the same concentration of R1881 to the aDMEM/F12K medium. Three 
tumors of PC295 and PC339 each were cultured under optimal conditions in 
aDMEM/F12K or in aDMEM/F12K supplemented with R1881. We found a 
significantly higher proliferation rate of the PC295 slices cultured in aDMEM/F12K 
supplemented with R1881 compared to aDMEM/F12K without R1881 (1.9 folds at day 
6) (Figure 3B). As expected, addition of R1881 did not affect proliferation rates of 
androgen independent PC339 slices (Figure 3B). Some increase in apoptosis was 
observed in PC339, while PC295 maintained its low apoptosis levels for up to 6 days 
of ex vivo culturing (Figure 3C). 
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To further assess tissue maintenance, we measured AR expression, a major 
characteristic of androgen dependent prostate tumors. Immunohistochemical stainings 
showed that AR expression was largely maintained during ex vivo culturing of PC295 
slices, with a small but significant decrease of AR expression in slices cultured at 6 
days in either PGM or aDMEM/F12K (Figure 4A and 4B). The addition of R1881 to 
aDMEM/F12K medium preserved AR levels up to 6 days of incubation (Figure 4C and 
4D). 
 Because androgen stimulates PSA secretion from PCa cells, we measured PSA 
levels in the culture media. Medium from PC295 tumor slices was collected for up to 6 
days and PSA accumulation was monitored. After normalization to initial PSA levels, 
we observed a continuous increase in PSA for up to 6 days in cultures supplemented 
with R1881 while slices cultured in aDMEM/F12K without R1881 showed a 
stabilization of PSA levels (Figure 4E). Altogether, we concluded that aDMEM/F12K 
plus R1881 is the optimal medium for maintenance of tissue slice morphology, viability, 
and AR-functionality. 
3.3 Enzalutamide treatment of tissue slices 
In order to validate the accuracy of the tissue slice system to reflect clinical responses 
to relevant therapies, we investigated the response to enzalutamide, a second generation 
anti-androgen which is currently being tested in a randomized phase III trial (25). 
PC295 (AR positive and androgen dependent) and PC339 (AR negative and androgen 
independent) slices were treated with enzalutamide with or without R1881. As shown 
in Figure 5A, we observed a significant drop in the fraction of EdU positive cells in 
PC295 slices treated with enzalutamide after 6 days of culturing (decreased by a factor 
of 5.5), while we did not observe a change in proliferation in PC339 slices. 
Simultaneously, a significant of 2.8 folds increase of TUNEL positive cells was 
observed in PC295 slices treated with enzalutamide, with no effect in the PC339 slices 
(Figure 5B). Presence of R1881 was unable to restore proliferation or revert apoptosis 
induced by enzalutamide treatment in PC295 slices (Figure 5A and 5B). AR staining of 
PC295 slices showed a dramatic reduction of 45% upon enzalutamide treatment at day 
6 which could also not be reversed by the presence of R1881 (Figure 5C). PSA 
measurement in medium samples further confirmed the inhibitory effect of 
enzalutamide on AR positive tumor slices. After an initial rise in PSA at day 2, PSA 
secretion decreased after enzalutamide treatment, both in presence or absence of R1881 
(Figure 5D). Similar anti-androgenic effects of enzalutamide were observed in tumor 
slices from the AR positive and androgen dependent PC310 PDX model (Figure S4) 
3.4  Olaparib treatment of tissue slices 
Mutations in the DNA repair gene BRCA2 have been identified in PCa patients, and 
previous studies have shown that these specific patients benefit from treatment with 
olaparib, an inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) (26). We therefore 
assessed the response to olaparib treatment in PC295 (BRCA2 wild type) and PC310 
(BRCA2 mutated) tumors. A significant drop in the fraction of S-phase cells was 
observed for both PC295 and PC310 tumor slices (decreased by a factor of 2.65 and 10, 
respectively) when treated with olaparib for 6 days, with a more pronounced reduction 
in cell proliferation for PC310 (Figure 6A). A significant increase of 10.9 fold of 
TUNEL positive cells was observed only in PC310 slices treated with olaparib, and not 
in PC295 tumor slices (Figure 6B). AR staining showed a significant reduction of AR 
positive tumor cells in PC310 tumor slices upon olaparib treatment, while only a 
slightly reduction of AR-positive tumor cell was observed in PC295 tumor slices 
(Figure 6C). PSA measurement revealed reduced PSA levels of both PC295 and PC310 
 
 
slices (Figure 6D). In conclusion, both BRCA2 deficient and proficient tumors are 
hampered by olaparib treatment, but only BRCA2 deficiency causes induction of 
apoptotic cell death. 
4. Discussion 
We have established an ex vivo tissue slice culture system using PCa PDXs. Under 
optimal culture conditions, tumor morphology, cell proliferation and prostatic 
characteristics are preserved for up to 6 days with minimal induction of cell death. 
Furthermore, we showed that this system is suitable for PCa drug testing: we observed 
responses to enzalutamide in androgen dependent tumor slices as well as to olaparib in 
BRCA2 mutant tumor slices that reflect in vivo therapy responses.  
An ex vivo tumor culture system should maintain cancer characteristics and tumor 
proliferating capacity during ex vivo culturing to allow reliable therapy response 
evaluation. Since the 1970s, various studies have been described that aim to establish 
an ex vivo culture system for PCa tumors. This has resulted in the development of 
different tumor culture methods, ranging from direct culturing of 1–2 mm3 human tissue 
samples in medium to more recently developed techniques to culture precision cut 
tissue slices on various scaffolds and supporting filters, like gelatin, collagen sponges 
or titanium mesh inserts (20,22,27-29). As reported in these studies, maintenance of 
prostate or PCa tissue slices for a week could be achieved, but maintenance of tissue 
structure and functionality was not always comprehensively reported with extensive 
variability in tissue origin and evaluation in the different studies. Application of the ex 
vivo culture system for drug testing was only reported in a few studies, describing 
reduced cell proliferation in response to genistein (28), cisplatin combined with a BcL-
2 antagonist (30), heat shock protein 90 inhibitors (27) , PARP-1 inhibitors (31) and 
most recently published studies with bicalutamide (29) and docetaxel (32). However 
detailed cell cycle progression (proliferation) of the tumor cells was not investigated, 
making direct comparison to our studies difficult. Importantly, our study validates the 
response to different tumor genotypes, represented by different PDXs, and hence 
provide evidence that ex vivo drug testing can indeed predict in vivo responses. 
Although ex vivo tumor cultures from other cancer types can be maintained for 
weeks or months (8,11,12,33-35), PCa tissue maintenance of primary tumors has been 
challenging probably due to the slow-growing characteristics and fast proliferation of 
basal cells (24,36,37). Also, obtaining aggressive metastatic PCa material is with 
limitations as metastatic disease is predominantly found in bone restricting easy excess. 
Nowadays, prostate-specific membrane antigen (PSMA) guided biopsy and salvage 
lymphadenectomy is reported (38-40), which may offer new opportunities for acquiring 
aggressive PCa material for ex vivo drug response tests. Our tissue slice culture platform 
for PCa defined in this study will be helpful to standardize ex-vivo culturing of patient 
material. 
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To further assess tissue maintenance, we measured AR expression, a major 
characteristic of androgen dependent prostate tumors. Immunohistochemical stainings 
showed that AR expression was largely maintained during ex vivo culturing of PC295 
slices, with a small but significant decrease of AR expression in slices cultured at 6 
days in either PGM or aDMEM/F12K (Figure 4A and 4B). The addition of R1881 to 
aDMEM/F12K medium preserved AR levels up to 6 days of incubation (Figure 4C and 
4D). 
 Because androgen stimulates PSA secretion from PCa cells, we measured PSA 
levels in the culture media. Medium from PC295 tumor slices was collected for up to 6 
days and PSA accumulation was monitored. After normalization to initial PSA levels, 
we observed a continuous increase in PSA for up to 6 days in cultures supplemented 
with R1881 while slices cultured in aDMEM/F12K without R1881 showed a 
stabilization of PSA levels (Figure 4E). Altogether, we concluded that aDMEM/F12K 
plus R1881 is the optimal medium for maintenance of tissue slice morphology, viability, 
and AR-functionality. 
3.3 Enzalutamide treatment of tissue slices 
In order to validate the accuracy of the tissue slice system to reflect clinical responses 
to relevant therapies, we investigated the response to enzalutamide, a second generation 
anti-androgen which is currently being tested in a randomized phase III trial (25). 
PC295 (AR positive and androgen dependent) and PC339 (AR negative and androgen 
independent) slices were treated with enzalutamide with or without R1881. As shown 
in Figure 5A, we observed a significant drop in the fraction of EdU positive cells in 
PC295 slices treated with enzalutamide after 6 days of culturing (decreased by a factor 
of 5.5), while we did not observe a change in proliferation in PC339 slices. 
Simultaneously, a significant of 2.8 folds increase of TUNEL positive cells was 
observed in PC295 slices treated with enzalutamide, with no effect in the PC339 slices 
(Figure 5B). Presence of R1881 was unable to restore proliferation or revert apoptosis 
induced by enzalutamide treatment in PC295 slices (Figure 5A and 5B). AR staining of 
PC295 slices showed a dramatic reduction of 45% upon enzalutamide treatment at day 
6 which could also not be reversed by the presence of R1881 (Figure 5C). PSA 
measurement in medium samples further confirmed the inhibitory effect of 
enzalutamide on AR positive tumor slices. After an initial rise in PSA at day 2, PSA 
secretion decreased after enzalutamide treatment, both in presence or absence of R1881 
(Figure 5D). Similar anti-androgenic effects of enzalutamide were observed in tumor 
slices from the AR positive and androgen dependent PC310 PDX model (Figure S4) 
3.4  Olaparib treatment of tissue slices 
Mutations in the DNA repair gene BRCA2 have been identified in PCa patients, and 
previous studies have shown that these specific patients benefit from treatment with 
olaparib, an inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) (26). We therefore 
assessed the response to olaparib treatment in PC295 (BRCA2 wild type) and PC310 
(BRCA2 mutated) tumors. A significant drop in the fraction of S-phase cells was 
observed for both PC295 and PC310 tumor slices (decreased by a factor of 2.65 and 10, 
respectively) when treated with olaparib for 6 days, with a more pronounced reduction 
in cell proliferation for PC310 (Figure 6A). A significant increase of 10.9 fold of 
TUNEL positive cells was observed only in PC310 slices treated with olaparib, and not 
in PC295 tumor slices (Figure 6B). AR staining showed a significant reduction of AR 
positive tumor cells in PC310 tumor slices upon olaparib treatment, while only a 
slightly reduction of AR-positive tumor cell was observed in PC295 tumor slices 
(Figure 6C). PSA measurement revealed reduced PSA levels of both PC295 and PC310 
 
 
slices (Figure 6D). In conclusion, both BRCA2 deficient and proficient tumors are 
hampered by olaparib treatment, but only BRCA2 deficiency causes induction of 
apoptotic cell death. 
4. Discussion 
We have established an ex vivo tissue slice culture system using PCa PDXs. Under 
optimal culture conditions, tumor morphology, cell proliferation and prostatic 
characteristics are preserved for up to 6 days with minimal induction of cell death. 
Furthermore, we showed that this system is suitable for PCa drug testing: we observed 
responses to enzalutamide in androgen dependent tumor slices as well as to olaparib in 
BRCA2 mutant tumor slices that reflect in vivo therapy responses.  
An ex vivo tumor culture system should maintain cancer characteristics and tumor 
proliferating capacity during ex vivo culturing to allow reliable therapy response 
evaluation. Since the 1970s, various studies have been described that aim to establish 
an ex vivo culture system for PCa tumors. This has resulted in the development of 
different tumor culture methods, ranging from direct culturing of 1–2 mm3 human tissue 
samples in medium to more recently developed techniques to culture precision cut 
tissue slices on various scaffolds and supporting filters, like gelatin, collagen sponges 
or titanium mesh inserts (20,22,27-29). As reported in these studies, maintenance of 
prostate or PCa tissue slices for a week could be achieved, but maintenance of tissue 
structure and functionality was not always comprehensively reported with extensive 
variability in tissue origin and evaluation in the different studies. Application of the ex 
vivo culture system for drug testing was only reported in a few studies, describing 
reduced cell proliferation in response to genistein (28), cisplatin combined with a BcL-
2 antagonist (30), heat shock protein 90 inhibitors (27) , PARP-1 inhibitors (31) and 
most recently published studies with bicalutamide (29) and docetaxel (32). However 
detailed cell cycle progression (proliferation) of the tumor cells was not investigated, 
making direct comparison to our studies difficult. Importantly, our study validates the 
response to different tumor genotypes, represented by different PDXs, and hence 
provide evidence that ex vivo drug testing can indeed predict in vivo responses. 
Although ex vivo tumor cultures from other cancer types can be maintained for 
weeks or months (8,11,12,33-35), PCa tissue maintenance of primary tumors has been 
challenging probably due to the slow-growing characteristics and fast proliferation of 
basal cells (24,36,37). Also, obtaining aggressive metastatic PCa material is with 
limitations as metastatic disease is predominantly found in bone restricting easy excess. 
Nowadays, prostate-specific membrane antigen (PSMA) guided biopsy and salvage 
lymphadenectomy is reported (38-40), which may offer new opportunities for acquiring 
aggressive PCa material for ex vivo drug response tests. Our tissue slice culture platform 
for PCa defined in this study will be helpful to standardize ex-vivo culturing of patient 
material. 
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Figure 5. Response to ex vivo enzalutamide treatment. 
A) Quantification of the fraction of EdU-positive cells for PC295 and PC339 slices at different time 
points. Scale bar 100 μm. B) Quantification of the fraction of TUNEL-positive cells for PC295 and 
PC339 slices at different time points. Scale bar 100 μm. C) Representative images of AR staining 
for PC295 tissue slice sections at day 6 and quantification of the AR stainings. Scale bar 50 μm. D) 
Normalized accumulated PSA concentrations of PC295 and PC339 slices from day 1 to day 6 treated 
or not with Enzalutamide. Line represent mean values and bars indicates SEM. Ten image fields for 
EdU/TUNEL and 4 image fields for AR were analyzed per tumor slice section. Each point represents 
one image field, average and SEM are indicated, four independent experiments for each tumor type. 
* P < 0.05, ** P < 0.01, *** P < 0.001, ns = non-significant. 
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Figure 5. Response to ex vivo enzalutamide treatment. 
A) Quantification of the fraction of EdU-positive cells for PC295 and PC339 slices at different time 
points. Scale bar 100 μm. B) Quantification of the fraction of TUNEL-positive cells for PC295 and 
PC339 slices at different time points. Scale bar 100 μm. C) Representative images of AR staining 
for PC295 tissue slice sections at day 6 and quantification of the AR stainings. Scale bar 50 μm. D) 
Normalized accumulated PSA concentrations of PC295 and PC339 slices from day 1 to day 6 treated 
or not with Enzalutamide. Line represent mean values and bars indicates SEM. Ten image fields for 
EdU/TUNEL and 4 image fields for AR were analyzed per tumor slice section. Each point represents 
one image field, average and SEM are indicated, four independent experiments for each tumor type. 
* P < 0.05, ** P < 0.01, *** P < 0.001, ns = non-significant. 
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Figure 6. Response to ex vivo olaparib treatment. 
A) Quantification of the fraction of EdU-positive cells of PC295 and PC310 slices treated with 
olaparib for 6 days. B) Quantification of the fraction of TUNEL positive cells of PC295 and PC310 
slices treated with olaparib for 6 days. C) Representative images of AR staining of PC295 and 
PC310 slices treated with olaparib for 6 days. Scale bar 50 μm. D) Normalized accumulated PSA 
concentrations of PC295 and PC310 slices from day 1 to day 6 treated or not with olaparib. Ten 
image fields for EdU/TUNEL and 4 image fields for AR were analyzed per tumor slice section. 
Each point represents one image field, average and SEM are indicated, three independent 
experiments for each tumor. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = non-significant. 
 
 
We used PDX tumors to thoroughly evaluate the impact of different culture 
condition and the ability of tissue slices to recapitulate individual tumor responses. PDX 
tumors have limited intra-tumoral heterogeneity and high tumor content which also 
allow us for intensive technical studies. For lowering slices heterogeneity within the 
same tumor, slices were consecutive allocated to each experimental treatment. We were 
able to keep longevity of tumor slices by using serum-free aDMEM/F12K medium with 
the addition of synthetic androgen up to 6 days. This medium shares many similar 
ingredients with medium PFMR-4A which was reported previously for successful 
maintenance of benign and malignant prostate tissue slices for 5 days (20). Serum-free 
medium allows more precise evaluations of cellular function and better control over 
physiological responsiveness.  
One of the strengths of this study is the use of EdU incorporation to assess cell 
proliferation, allowing real time measurement of DNA synthesis during replication. We 
believe that this is a more reliable way to measure early treatment effects compared to 
the commonly used Ki67 marker. Ki67 protein is present in all cycling cells, even for 
several days after cells have ceased to proliferate (41). Indeed, we observed a disparity 
between EdU ratio and Ki67 expression: after 6 days culturing EdU ratio dropped 
significantly while Ki67 only showed a slight reduction (Figure S5). In the majority of 
tumor slices from all three PDXs tested, we observed an increase of proliferation after 
one day of incubation, followed by constant homogenous maintenance of proliferation 
(PC339 and PC310) or slightly decrease of proliferation (PC295). The first-day 
proliferation boost might be a result of the availability of a high level of nutrients and 
oxygen. The initial high TUNEL level in PC339 slices is most likely due to a higher 
level of necrosis in the original tumor sample, since TUNEL assay is unable to 
distinguish necrosis and apoptosis (42). 
We observed a marginal effect of androgen deprivation on tumor slice viability in 
androgen responsive PDX tissue slices. This might be caused by the presence of 
endogenous androgen maintained in the tumor slices and which is gradually released 
into the medium during culturing. Thus, endogenously present androgen can be used to 
maintain activation of AR signaling and proliferation for a few days. Similar 
observations were done by Zhou et al. in rat prostates that retained similar androgen 
tissue levels independent of the serum concentrations (43) . 
A clear anti-androgenic response to enzalutamide was observed in androgen 
dependent tissue slices. Our ex vivo response of tissue slices to enzalutamide are also 
supported by in vivo data reported by Guerrero et al. in which enzalutamide inhibits 
tumor growth significantly during the first 6 days of treatment compared with vehicle-
treated mice (44). Additionally, we showed that olaparib induced cell death in the 
BRCA2 mutant PC310 tumor slices, confirming the expected response when targeting 
DNA damage repair deficient tumors. This was in concordance with recent clinical 
studies, showing that that CRPC patients with somatic loss and germline mutation of 
BRCA2 respond well to olaparib (26). Similar was reported by Beshiri et al. for PCa 
PDX organoid cultures in which BRCA2 deficiency correlates with olaparib sensitivity 
(45). PARP-1 inhibitors with high PARP trapping potency, such as olaparib, can yield 
intense replication stress (46,47), which can explain the decrease of fraction of S-phase 
cells in the BRCA2 wild type PC295 slices.  
So far, several publications have suggested that tumor tissue slice culture can be 
utilized to predict drug response in breast cancer (8-10) and monitor cytotoxic drug 
effects in liver, intestine and lung (48-50). We have established dedicated tissue slice 
system for PCa that shows robust and specific anti-androgen and PARP-1 inhibition 
treatment effects and that can be extended to testing of novel compounds relevant to 
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Figure 6. Response to ex vivo olaparib treatment. 
A) Quantification of the fraction of EdU-positive cells of PC295 and PC310 slices treated with 
olaparib for 6 days. B) Quantification of the fraction of TUNEL positive cells of PC295 and PC310 
slices treated with olaparib for 6 days. C) Representative images of AR staining of PC295 and 
PC310 slices treated with olaparib for 6 days. Scale bar 50 μm. D) Normalized accumulated PSA 
concentrations of PC295 and PC310 slices from day 1 to day 6 treated or not with olaparib. Ten 
image fields for EdU/TUNEL and 4 image fields for AR were analyzed per tumor slice section. 
Each point represents one image field, average and SEM are indicated, three independent 
experiments for each tumor. * P < 0.05, ** P < 0.01, *** P < 0.001, ns = non-significant. 
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We observed a marginal effect of androgen deprivation on tumor slice viability in 
androgen responsive PDX tissue slices. This might be caused by the presence of 
endogenous androgen maintained in the tumor slices and which is gradually released 
into the medium during culturing. Thus, endogenously present androgen can be used to 
maintain activation of AR signaling and proliferation for a few days. Similar 
observations were done by Zhou et al. in rat prostates that retained similar androgen 
tissue levels independent of the serum concentrations (43) . 
A clear anti-androgenic response to enzalutamide was observed in androgen 
dependent tissue slices. Our ex vivo response of tissue slices to enzalutamide are also 
supported by in vivo data reported by Guerrero et al. in which enzalutamide inhibits 
tumor growth significantly during the first 6 days of treatment compared with vehicle-
treated mice (44). Additionally, we showed that olaparib induced cell death in the 
BRCA2 mutant PC310 tumor slices, confirming the expected response when targeting 
DNA damage repair deficient tumors. This was in concordance with recent clinical 
studies, showing that that CRPC patients with somatic loss and germline mutation of 
BRCA2 respond well to olaparib (26). Similar was reported by Beshiri et al. for PCa 
PDX organoid cultures in which BRCA2 deficiency correlates with olaparib sensitivity 
(45). PARP-1 inhibitors with high PARP trapping potency, such as olaparib, can yield 
intense replication stress (46,47), which can explain the decrease of fraction of S-phase 
cells in the BRCA2 wild type PC295 slices.  
So far, several publications have suggested that tumor tissue slice culture can be 
utilized to predict drug response in breast cancer (8-10) and monitor cytotoxic drug 
effects in liver, intestine and lung (48-50). We have established dedicated tissue slice 
system for PCa that shows robust and specific anti-androgen and PARP-1 inhibition 
treatment effects and that can be extended to testing of novel compounds relevant to 
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PCa. 
 
5. Conclusions  
The faithful retention of tissue structure and function in our ex vivo culture system offers 
an opportunity to evaluate PCa response to therapeutic compounds making it an ideal 
system for low to medium throughput testing in drug discovery. 
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Supplementary files 
 
Figure S1. Effect of filter support and 3D orbital movement on PCa tissue slice 
morphology  
Representative H&E images of PC339 and PC310 tumor slice sections after 4 days of culturing 
under the different culture conditions, compared to an initial slice (day 0). 
 
 
Figure S2. Correlation between manual counting and automatic counting. 
EdU staining micrographs were randomly selected to test the reliability of the quantification 
algorithm. Manual counting results from two persons were compared to automatic counting results. 
 
  
 
 
 
Figure S3. Effect of different media on tissue slice morphology. 
Representative H&E images of PC295 tumor slice section after 4 days of culturing under different 
culture media.  
 
 
Figure S4. Ex-vivo Enzalutamide treatment effect on PC310 tumor  
A). Quantification of the EdU-positive cell ratio of PC310 slices treatment with Enzalutamide, 10 
image fields were analyzed per tumor slice. B) Quantification of the TUNEL-positive ratio of PC310 
slices treated with Enzalutamide, 10 image fields were analyzed per tumor slice. C) Quantification 
of AR staining. Four image fields were analyzed per tumor slice (magnification ×100). Each point 
represents one image field, average and SEM are indicated. D) Normalized PSA concentration in 
culture medium. (N=3). *** P < 0.001. 
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Figure S5. Double staining of Ki67 and EdU  
Quantification of the Ki67 and EdU-positive cell ratio in PC295 slices cultured in aDMEM/F12K 
for different time points. 
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Abstract 
Androgen-deprivation therapy was shown to improve treatment outcome of external 
beam radiation therapy (EBRT) for locally advanced prostate cancer (PCa). DNA 
damage response (DDR) was suggested to play a role in the underlying mechanism, but 
conflicting results were reported. This study aims to reveal the role of the androgen 
receptor (AR) in EBRT-induced DDR and to investigate whether next-generation AR 
inhibitor apalutamide can radiosensitize PCa. PCa cell lines and tissue slices were 
treated with anti-androgen alone or combined with EBRT. The effect of treatments on 
cell growth, tissue viability, DDR, and cell cycle were investigated. RAD51 and DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) levels were determined by 
Western blotting. Homologous recombination (HR) capacity was measured with the 
directed repeats-green fluorescent protein (DR-GFP) assay. We report the 
radiosensitizing effect of anti-androgens, which showed synergism in combination with 
EBRT in AR-expressing tumor slices and cell lines. Moreover, a compromised DDR 
was observed in AR-expressing cells upon AR suppression. We found that AR 
inhibition downregulated DNA-PKcs expression, resulting in reduced non-homologous 
end-joining repair. DDR through HR was a secondary effect due to cell-cycle change. 
These data provide a mechanistic explanation for the combination regimen and support 
the clinical use of apalutamide together with EBRT for localized PCa patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. Introduction 
Prostate Cancer (PCa) is the most common malignancy and the second cause of cancer-
related death among men (1). External beam radiation therapy (EBRT) is the first line 
of treatment for locally advanced PCa, but unfortunately tumors frequently recur after 
treatment (2, 3). The combination of EBRT with androgen-deprivation therapy (ADT), 
the first line systemic treatment for advanced PCa, has shown to improve the overall 
therapeutic outcome compared to EBRT alone (4-6). Blocking activation of the 
androgen receptor (AR) signaling pathway by ADT is highly effective in reducing PCa 
tumor growth, therefore, preclinical studies and clinical trials have not been able to 
assess whether the addition of ADT to EBRT induces a synergistic or additive effect. 
Moreover, conflicting results have been reported on the underlying cellular mechanisms 
causing this effect. Interestingly, recent studies have indicated that AR signaling can 
activate DNA repair pathways, which may contribute to radioresistance (7, 8). 
Ionizing radiation (IR) induces DNA double-strand breaks (DSBs), which can be 
repaired by two main pathways: non-homologous end-joining (NHEJ) and homologous 
recombination (HR). NHEJ involves recruitment of DNA dependent protein kinase 
catalytic subunit (DNA-PKcs) to DNA ends by the Ku70/80 heterodimer, followed by 
coupling of the DNA ends. HR is mediated by the RAD51 protein in combination with 
many other factors such as breast cancer 1 and 2 (BRCA1 or 2) (9). AR activation 
promotes upregulation of DNA-PKcs, Ku70/80 and RAD51, however it is unclear 
whether AR directly regulates expression of these genes and previous studies contain 
conflicting findings on DNA repair pathway regulation (7, 8, 10, 11). 
Apalutamide (ERLEADA®) is a next-generation AR inhibitor which has been 
approved in 2018 for treatment of non-metastatic castration-resistant prostate cancer 
(CRPC). Apalutamide blocks AR activation by competing with androgen binding and 
preventing AR translocation to the nucleus. It has a 5- to 10- fold higher binding affinity 
than the first-generation anti-androgen bicalutamide, which has been widely used for 
PCa patient treatment (12). Also, apalutamide showed a greater efficacy compared to 
the second-generation anti-androgen enzalutamide (12), which was shown in 
preclinical studies to have radiosensitizing capacities (13). Ongoing clinical trials are 
testing the efficacy of combination treatment of apalutamide and EBRT; however, 
preclinical data are yet to be presented to support this combination. 
Here, we compared the radiosensitizing capacity of apalutamide to ADT and 
enzalutamide in PCa cell and ex vivo patient-derived xenograft (PDX) tissue slice 
models. Furthermore, we identified NHEJ downregulation as the underlying 
mechanism of apalutamide-enhanced radiosensitivity in AR-expressing PCa models. 
2. Results 
2.1. AR suppression enhances IR-induced cell killing 
The impact of AR suppression treatments on PCa cell response to IR exposure was 
studied by applying ADT, enzalutamide or apalutamide 24 hours prior to IR. The IR 
dose per cell lines was chosen such that cell proliferation was not fully inhibited (data 
not shown). AR suppression alone reduced the total cell number with 50% in LNCaP 
and 40% in PC346C cells 7 days post-IR, and IR treatment alone reduced the total cell 
number with 20% in LNCaP and 35% in PC346C cells (Fig. 1A). The combination 
treatment resulted in a further reduction of the total cell number of 65% and 70% for 
LNCaP and PC346C cells, respectively. As expected, AR suppression did not affect 
cell number in AR-negative DU145 and PC346C-DCC cells, and the addition of AR 
suppression to IR exposure did not cause additional sensitivity (Fig. 1B). In AR-
overexpressing PC346C-Flu1 cells, AR suppression did not affect cell growth, 
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reflecting the CRPC nature of this cell line. Interestingly, combining AR suppression 
and IR treatments resulted in a small, but significant reduction of the total cell number 
with 40% at 7 days post-IR compared to IR alone (20%) (Fig. 1C). No significant 
difference was observed between the different AR suppression treatments. These data 
suggest that there is an additional effect of the combination treatment compared to IR 
alone, which is dependent on the AR status of the tumor cells. 
2.2. Apalutamide enhances PCa tissue slice IR sensitivity 
Subsequently, we investigated the effects of apalutamide on IR sensitivity in androgen-
dependent, AR-positive PC295 ex vivo tumor slices (14). Tumor slices retained 
morphology 6 days post IR-exposure, while treatment with apalutamide resulted in 
tissue integrity loss, loss of AR-expression (Fig. 2A-B) and significantly reduced tissue 
slice viability with reduced fraction of S-phase cells and increased number of apoptotic 
cells (Fig. 2C-E). 2 Gy of IR had no effect on tissue slice viability, with neither a 
reduction of S-phase cells nor an increase of apoptotic cells at any time point. 
Combination of IR and apalutamide, significantly reduced the level of S-phase cells 
and increased the level of apoptotic cells already at day 1 after IR at which no effect of 
the single treatments can be detected, indicating a synergy between these two treatments. 
This effect became more prominent over time (Fig. 2C-E). The combination treatment 
did not further reduce AR expression level compared to apalutamide treatment alone 
(Fig. 2A-B). Together, these data show the synergistic effect of IR and apalutamide 
treatment in this PCa tumor model. 
2.3. AR suppression inhibits DNA damage repair 
Next, we investigated whether AR suppression treatment enhanced IR sensitivity could 
result from a DSB repair defect by measuring DSB repair kinetics of PCa cells. AR 
suppression treatment alone did not increase DSB foci numbers compared to untreated 
controls (Fig. S1). IR exposure resulted in rapid induction of DSBs, measured by 
γH2AX and 53BP1 foci staining, in all 3 cell lines tested (Fig. 3A-B). At 1 and 24 hours 
after IR, cells in the combination therapy groups showed significantly more DSB foci 
than cells treated with IR alone, indicative of a slower repair of DSBs or higher level 
of DNA damage (Figure 3A-B). An alternative explanation for the increase of foci 
numbers could be the increased DNA content per nucleus in the S/G2 phase of the cell 
cycle. Therefore, we analyzed the cell cycle distribution 24 hours post-IR. The fraction 
of S/G2 cells was not increased by AR suppression treatment in PC346C and PC346C-
Flu1 cells (Fig. S2), while LNCaP cells displayed an even higher fraction of G1 phase 
cells, a cell phase with less DNA content, excluding a cell cycle effect. 
In addition to indirect measurement of the level of DSBs using γH2AX and 53BP1 
foci quantifications, we also measured the number of DNA breaks by PFGE. AR 
suppression as single treatment did not cause increased levels of broken DNA, while 
IR exposure did. No difference was observed between control and AR suppression 
treatment directly after IR exposure, indicating that the same level of DNA breaks was 
induced (Fig. 3C-D). When allowing cells to repair the DNA damage for 1 hour, a 
significantly higher level of DNA breaks was observed in AR suppression treated cells 
compared with control group (Fig. 3C-D). This effect is robust in both androgen-
dependent and CRPC AR-expressing cells, but was absent in AR-negative DU145 cells 
(Fig. 3C-D). Combined, these data indicate that AR suppression inhibits repair of IR-
induced DSBs and that this effect is dependent on AR-expression. 
 
  
 
Figure 1. AR suppression treatment inhibits cell growth cooperatively with IR 
treatment in AR-positive PCa cells. 
Cells were pretreated with AR suppression or DMSO control for 24 h followed by IR treatment. 
The cell number was measured at day 7 post-treatment with a sulforhodamine beta (SRB) assay and 
set relative to initial cell number followed by normalized to untreated control. (a) Androgen receptor 
(AR)-positive and androgen-dependent (AD) LNCaP and PC346C. (b) AR-negative, castration-
resistant prostate cancer (CRPC) PC346C-DCC and DU145 cells. (c) AR-positive and CRPC 
PC346C-Flu1 cells. Average and SEM are indicated, *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-
significant, ADT, androgen-deprivation treatment; APA, apalutamide; ENZA, enzalutamide. 
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The cell number was measured at day 7 post-treatment with a sulforhodamine beta (SRB) assay and 
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resistant prostate cancer (CRPC) PC346C-DCC and DU145 cells. (c) AR-positive and CRPC 
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Figure 2. Apalutamide radiosensitizes PCa tissue slices ex vivo. 
Androgen receptor (AR)-positive, androgen-dependent PC295 PDX slices were pretreated 
with apalutamide (APA) for 2 h followed by 2 Gy IR treatment. (a) Representative H&E and 
AR immunostaining images of tumor slice sections after 6 days of culturing under different 
conditions. Scale bar 20 μm. (b) Quantification of AR expression. Four image fields were 
analyzed per tumor slice, each data point represents one image field, average and SEM are 
indicated. (c) Representative DAPI/EdU/TUNEL images of tumor slice sections after 6 days 
of culturing under different conditions, scale bar 20 μm. (d) Quantification of the fraction of 
EdU-positive cells in the tissue slices. (e) Quantification of the fraction of TUNEL positive 
cells in the tissue slices. For EdU and TUNEL graphs, 10 image fields were analyzed per tumor 
slice. Each data point represents one image field, average and SEM are indicated. **P < 0.01, 
***P < 0.001, ns, non-significant. 
2.4. Reduced HR efficiency provoked by AR suppression results from cell cycle 
alterations 
Subsequently, we investigated whether AR suppression directly affected HR. Since 
previous studies have reported reduced RAD51 expression after enzalutamide treatment 
(10), we measured change in the RAD51 protein level after the different AR 
suppression treatments. In LNCaP cells, a reduction of RAD51 expression was detected 
upon AR suppression (statistically significant after ADT and enzalutamide treatment) 
(Fig. 4A-B). However, PC346C and PC346C-Flu1 cells did not show similar decrease 
in RAD51 levels after AR suppression treatment (Fig. 4A-B). Cell cycle analysis 
revealed a significant reduction of the fraction of S-phase cells in LNCaP cells, while 
no change was observed in PC346C and PC346C-Flu1 cells (Fig. 4C). Since RAD51 is 
  
only expressed in S/G2 phase cells, this suggests that reduced RAD51 levels may be 
secondary to cell cycle distribution changes. To further substantiate this finding, the 
effect of apalutamide treatment on HR was directly assessed using the DR-GFP assay. 
Apalutamide treatment caused 50% reduction of HR in LNCaP cells (Fig. 4D), while 
PC346C-Flu1 cells were not affected. As a control, knockdown of the BRCA1 protein 
successfully reduced HR capacity more than 50% in both cell lines (Fig. 4D). Since HR 
functionality was reduced upon apalutamide treatment only in LNCaP cells, these data 
suggest again that this may be caused by a reduced fraction of S/G2 cells (Fig. 4C). To 
confirm that HR capacity was not affected in S/G2 cells, we measured HR functionality 
by RAD51 foci formation in EdU-positive cells. RAD51 foci formation in S-phase cells 
was not changed by AR suppression in both LNCaP and PC346C-Flu1 cells (Fig. 4E-
F). Taken together, these data indicate that HR efficiency is not directly inhibited by 
AR suppression, but only a secondary effect of cell cycle alteration.  
2.5. NHEJ inhibition by AR suppression contributed to radiosensitization  
After excluding the HR pathway as the direct cause of AR suppression induced 
radiosensitization, we investigated the involvement of the NHEJ pathway. Previously, 
Goodwin et al. showed that the AR pathway regulates the NHEJ factor DNA-PKcs (7). 
Therefore, we analyzed DNA-PKcs protein expression after AR suppression treatment. 
A significant reduction of the DNA-PKcs protein level was observed in all 3 cell lines 
(Fig. 5A-B). On average, all AR suppression modalities reduced DNA-PKcs levels to 
30-60 %. We further investigated whether these reduced DNA-PKcs levels were 
sufficient to explain the observed DSB repair defects (Fig. 3). To this end, PC346C-
Flu1 cells were treated with small interfering RNA (siRNA) to reduce DNA-PKcs 
expression. This cell line was selected since HR was shown to be unaffected, allowing 
us to determine if reduction of NHEJ repair could explain the observed synergistic 
therapy response. DNA-PKcs expression was reduced to approximately 50% by siRNA 
treatment, similar to DNA-PKcs levels observed after AR suppression. A significantly 
decreased ability to repair DSBs was observed at 24 hours after IR compared to control 
cells (Fig. 5C-D). DNA-PKcs knockdown did show significant difference in γH2AX 
and 53BP1 foci levels at 1 hour post-IR as was observed for AR suppression treatments. 
Furthermore, PFGE analysis also showed a higher level of DNA breaks at 1 hour after 
IR in cells with reduced DNA-PKcs levels compared to control cells (Fig. 5E-F). The 
functional consequences of DNA-PKcs reduction were directly assessed and these cells 
showed a significant reduced cell number after IR treatment compared to cells with 
normal levels of DNA-PKcs (Fig. 5G). These results indicate that reduced DNA-PKcs 
expression caused by AR suppression treatment can at least partially account for the 
observed delay in DSB repair and the associated radiosensitization. 
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Figure 2. Apalutamide radiosensitizes PCa tissue slices ex vivo. 
Androgen receptor (AR)-positive, androgen-dependent PC295 PDX slices were pretreated 
with apalutamide (APA) for 2 h followed by 2 Gy IR treatment. (a) Representative H&E and 
AR immunostaining images of tumor slice sections after 6 days of culturing under different 
conditions. Scale bar 20 μm. (b) Quantification of AR expression. Four image fields were 
analyzed per tumor slice, each data point represents one image field, average and SEM are 
indicated. (c) Representative DAPI/EdU/TUNEL images of tumor slice sections after 6 days 
of culturing under different conditions, scale bar 20 μm. (d) Quantification of the fraction of 
EdU-positive cells in the tissue slices. (e) Quantification of the fraction of TUNEL positive 
cells in the tissue slices. For EdU and TUNEL graphs, 10 image fields were analyzed per tumor 
slice. Each data point represents one image field, average and SEM are indicated. **P < 0.01, 
***P < 0.001, ns, non-significant. 
2.4. Reduced HR efficiency provoked by AR suppression results from cell cycle 
alterations 
Subsequently, we investigated whether AR suppression directly affected HR. Since 
previous studies have reported reduced RAD51 expression after enzalutamide treatment 
(10), we measured change in the RAD51 protein level after the different AR 
suppression treatments. In LNCaP cells, a reduction of RAD51 expression was detected 
upon AR suppression (statistically significant after ADT and enzalutamide treatment) 
(Fig. 4A-B). However, PC346C and PC346C-Flu1 cells did not show similar decrease 
in RAD51 levels after AR suppression treatment (Fig. 4A-B). Cell cycle analysis 
revealed a significant reduction of the fraction of S-phase cells in LNCaP cells, while 
no change was observed in PC346C and PC346C-Flu1 cells (Fig. 4C). Since RAD51 is 
  
only expressed in S/G2 phase cells, this suggests that reduced RAD51 levels may be 
secondary to cell cycle distribution changes. To further substantiate this finding, the 
effect of apalutamide treatment on HR was directly assessed using the DR-GFP assay. 
Apalutamide treatment caused 50% reduction of HR in LNCaP cells (Fig. 4D), while 
PC346C-Flu1 cells were not affected. As a control, knockdown of the BRCA1 protein 
successfully reduced HR capacity more than 50% in both cell lines (Fig. 4D). Since HR 
functionality was reduced upon apalutamide treatment only in LNCaP cells, these data 
suggest again that this may be caused by a reduced fraction of S/G2 cells (Fig. 4C). To 
confirm that HR capacity was not affected in S/G2 cells, we measured HR functionality 
by RAD51 foci formation in EdU-positive cells. RAD51 foci formation in S-phase cells 
was not changed by AR suppression in both LNCaP and PC346C-Flu1 cells (Fig. 4E-
F). Taken together, these data indicate that HR efficiency is not directly inhibited by 
AR suppression, but only a secondary effect of cell cycle alteration.  
2.5. NHEJ inhibition by AR suppression contributed to radiosensitization  
After excluding the HR pathway as the direct cause of AR suppression induced 
radiosensitization, we investigated the involvement of the NHEJ pathway. Previously, 
Goodwin et al. showed that the AR pathway regulates the NHEJ factor DNA-PKcs (7). 
Therefore, we analyzed DNA-PKcs protein expression after AR suppression treatment. 
A significant reduction of the DNA-PKcs protein level was observed in all 3 cell lines 
(Fig. 5A-B). On average, all AR suppression modalities reduced DNA-PKcs levels to 
30-60 %. We further investigated whether these reduced DNA-PKcs levels were 
sufficient to explain the observed DSB repair defects (Fig. 3). To this end, PC346C-
Flu1 cells were treated with small interfering RNA (siRNA) to reduce DNA-PKcs 
expression. This cell line was selected since HR was shown to be unaffected, allowing 
us to determine if reduction of NHEJ repair could explain the observed synergistic 
therapy response. DNA-PKcs expression was reduced to approximately 50% by siRNA 
treatment, similar to DNA-PKcs levels observed after AR suppression. A significantly 
decreased ability to repair DSBs was observed at 24 hours after IR compared to control 
cells (Fig. 5C-D). DNA-PKcs knockdown did show significant difference in γH2AX 
and 53BP1 foci levels at 1 hour post-IR as was observed for AR suppression treatments. 
Furthermore, PFGE analysis also showed a higher level of DNA breaks at 1 hour after 
IR in cells with reduced DNA-PKcs levels compared to control cells (Fig. 5E-F). The 
functional consequences of DNA-PKcs reduction were directly assessed and these cells 
showed a significant reduced cell number after IR treatment compared to cells with 
normal levels of DNA-PKcs (Fig. 5G). These results indicate that reduced DNA-PKcs 
expression caused by AR suppression treatment can at least partially account for the 
observed delay in DSB repair and the associated radiosensitization. 
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Figure 4. Reduced HR efficiency provoked by AR suppression treatment results  
from cell cycle alterations.  
(a) LNCaP, PC346C and PC346C-Flu1 cells were treated with AR suppression for 48 h and 
RAD51 expression was analyzed by Western blotting. Tubulin is used as loading control. Full 
blots can be found in supplementary Figure 3. (b) Quantification of RAD51 protein levels 
compared to loading control and normalized to untreated (Ctrl). Average and SEM are 
indicated. (c) The same cell samples from a were incubated with EdU for 30 min before 
fixation and the cell cycle profile was determined by flow cytometry. Average and SD are 
indicated. (d) Transient DR-GFP assay was performed in LNCaP and PC346C-Flu1 cells 
treated with apalutamide for 48 h. Cells transfected with siRNA against BRCA1 transcript for 
72 h were used as positive control. GFP positive cells were scored by flow cytometry and 
quantified. Average and SD are indicated. (e) Representative images of double staining of 
EdU-positive and RAD51 foci and their colocalization in LNCaP cells at 2 h after 5 Gy IR 
treatment (scale bar 10 μm). (f) Quantification of RAD51 foci numbers in EdU-positive cells. 
Each data point represents one cell, average and SEM are indicated. *P < 0.05, **P < 0.01, ns, 
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Figure 4. Reduced HR efficiency provoked by AR suppression treatment results  
from cell cycle alterations.  
(a) LNCaP, PC346C and PC346C-Flu1 cells were treated with AR suppression for 48 h and 
RAD51 expression was analyzed by Western blotting. Tubulin is used as loading control. Full 
blots can be found in supplementary Figure 3. (b) Quantification of RAD51 protein levels 
compared to loading control and normalized to untreated (Ctrl). Average and SEM are 
indicated. (c) The same cell samples from a were incubated with EdU for 30 min before 
fixation and the cell cycle profile was determined by flow cytometry. Average and SD are 
indicated. (d) Transient DR-GFP assay was performed in LNCaP and PC346C-Flu1 cells 
treated with apalutamide for 48 h. Cells transfected with siRNA against BRCA1 transcript for 
72 h were used as positive control. GFP positive cells were scored by flow cytometry and 
quantified. Average and SD are indicated. (e) Representative images of double staining of 
EdU-positive and RAD51 foci and their colocalization in LNCaP cells at 2 h after 5 Gy IR 
treatment (scale bar 10 μm). (f) Quantification of RAD51 foci numbers in EdU-positive cells. 
Each data point represents one cell, average and SEM are indicated. *P < 0.05, **P < 0.01, ns, 
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non-significant. ADT, androgen deprivation treatment; APA, apalutamide; ENZA, 
enzalutamide. 
 
 
Figure 5. NHEJ suppression is regulated by AR signaling and contributes to 
radiosensitization.  
(a) LNCaP, PC346C and PC346C-Flu1 cells were treated with AR suppression for 48 h and 
DNA-PKcs protein levels were analyzed by Western blotting. Tubulin is used as loading 
control. Full blots can be found in supplementary Figure 3. (b) Quantification of DNA-PKcs 
protein levels compared to loading control and normalized to untreated (Ctrl). Average and 
SEM are indicated. (c) PC346C-Flu1 cells were transfected with a pool of siRNAs against the 
DNA-PKcs or non-targeting siRNA for 48 h then treated with 2 Gy IR treatment. 
Representative images of γH2AX and 53BP1 stainings 24 h post-IR (scale bar 10 μm). (d) 
Quantification of γH2AX and 53BP1 foci. Each data point represents one cell, average and 
SEM are indicated. (e) Representative pulsed-field gel electrophoresis (PFGE) image of 
PC346C-Flu1 cells were treated as in C but following treated with 15 Gy IR. (f) DNA break 
signals were quantified by ImageJ and normalized to unsaturated signals of intact DNA. 
Average and SD are indicated. (g) PC346C-Flu1 were treated as in C but followed with 1 Gy 
IR treatment, and cells were counted 7 days after treatment by sulforhodamine beta (SRB) 
assay and cell number set relative to initial cell number. *P < 0.05, **P < 0.01, ***P < 0.0001, 
  
ns, non-significant. ADT, androgen deprivation treatment; APA, apalutamide; ENZA, 
enzalutamide. 
3. Discussion 
Here, we demonstrate that different forms of AR suppression treatment can act as a 
radiosensitizer in AR-expressing androgen-dependent and CRPC preclinical PCa 
models. The mechanism of action causing this radiosensitization involves regulation of 
the NHEJ DNA repair pathway. 
We and others found that AR suppression and IR treatment have an additive effect 
on cell proliferation in AR-expressing PCa (7, 13). Based on these data, AR suppression 
treatments were reported to have a radiosensitizing effect. However, the observed 
effects could also be explained by additivity of both modalities. Previous reports come 
to opposing conclusions regarding the radiosensitizing effect of AR suppression in 
CRPC models, with studies showing a synergistic effect (7, 15) or no effect (13, 16). 
Our in vitro CRPC cells and ex vivo androgen-dependent PCa tissue slices experiments 
provide new evidence that AR suppression can act as radiosensitizer in both AR-
expressing hormone-sensitive PCa (which represents the majority of patients receiving 
EBRT) and AR-expressing CRPC. Although no synergy could be demonstrated in cell 
growth assays, our DSB repair kinetic assays showed a clear synergy between IR and 
AR suppression treatment for AR-expressing PCa cells. We found similar effects of 
apalutamide, enzalutamide and ADT, showing that various methods of AR suppression 
have similar efficacy in vitro. We conclude that patients with AR-expressing PCa can 
benefit from apalutamide or other AR suppressing treatment in addition to EBRT.  
Previous preclinical studies have investigated the molecular mechanism of 
radiosensitization by ADT and discovered an interplay between AR-signaling and the 
DNA repair machinery (7, 8, 10, 11, 16). However, opposing conclusions were drawn 
from these studies about the DNA repair pathways that cause the radiosensitization. 
Studies reported a functional link between AR-signaling and HR repair and synthetic 
lethality in combinations of AR inhibitors and PARP inhibitors in PCa. Enzalutamide 
suppressed the expression of the HR protein RAD51 in androgen-dependent PCa cells 
(10) and HR efficiency, measured by a functional HR assay, was indeed significantly 
reduced by AR suppression (10, 11, 16). We found that reduced RAD51 expression and 
compromised HR could be explained by a reduced fraction of S/G2 phase cells. Such 
cell cycle analyses were not included in their studies, which precludes definitive 
conclusions. Asim et al. showed that IR-induced RAD51 foci formation in Ki67-
positive PCa cells were strongly decreased in patient biopsies who received ADT (11). 
This is seemingly in contrast with our results that equal numbers of RAD51 foci were 
detected in EdU-positive cells after AR suppression. However, this discrepancy can be 
explained by the difference in detection of proliferating cells: EdU labels only S-phase 
cells, whereas Ki67 is present in all cycling cells. It has even been reported to persist 
for several days after cells have ceased to proliferate (17). Ki67 positive cells may thus 
be primarily G1 phase cells that do not form RAD51 foci nor perform HR. Together, 
our data indicate that the HR pathway is not directly regulated by AR-signaling, but 
HR might be reduced on a cell population level caused by a change of the cell cycle 
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(a) LNCaP, PC346C and PC346C-Flu1 cells were treated with AR suppression for 48 h and 
DNA-PKcs protein levels were analyzed by Western blotting. Tubulin is used as loading 
control. Full blots can be found in supplementary Figure 3. (b) Quantification of DNA-PKcs 
protein levels compared to loading control and normalized to untreated (Ctrl). Average and 
SEM are indicated. (c) PC346C-Flu1 cells were transfected with a pool of siRNAs against the 
DNA-PKcs or non-targeting siRNA for 48 h then treated with 2 Gy IR treatment. 
Representative images of γH2AX and 53BP1 stainings 24 h post-IR (scale bar 10 μm). (d) 
Quantification of γH2AX and 53BP1 foci. Each data point represents one cell, average and 
SEM are indicated. (e) Representative pulsed-field gel electrophoresis (PFGE) image of 
PC346C-Flu1 cells were treated as in C but following treated with 15 Gy IR. (f) DNA break 
signals were quantified by ImageJ and normalized to unsaturated signals of intact DNA. 
Average and SD are indicated. (g) PC346C-Flu1 were treated as in C but followed with 1 Gy 
IR treatment, and cells were counted 7 days after treatment by sulforhodamine beta (SRB) 
assay and cell number set relative to initial cell number. *P < 0.05, **P < 0.01, ***P < 0.0001, 
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3. Discussion 
Here, we demonstrate that different forms of AR suppression treatment can act as a 
radiosensitizer in AR-expressing androgen-dependent and CRPC preclinical PCa 
models. The mechanism of action causing this radiosensitization involves regulation of 
the NHEJ DNA repair pathway. 
We and others found that AR suppression and IR treatment have an additive effect 
on cell proliferation in AR-expressing PCa (7, 13). Based on these data, AR suppression 
treatments were reported to have a radiosensitizing effect. However, the observed 
effects could also be explained by additivity of both modalities. Previous reports come 
to opposing conclusions regarding the radiosensitizing effect of AR suppression in 
CRPC models, with studies showing a synergistic effect (7, 15) or no effect (13, 16). 
Our in vitro CRPC cells and ex vivo androgen-dependent PCa tissue slices experiments 
provide new evidence that AR suppression can act as radiosensitizer in both AR-
expressing hormone-sensitive PCa (which represents the majority of patients receiving 
EBRT) and AR-expressing CRPC. Although no synergy could be demonstrated in cell 
growth assays, our DSB repair kinetic assays showed a clear synergy between IR and 
AR suppression treatment for AR-expressing PCa cells. We found similar effects of 
apalutamide, enzalutamide and ADT, showing that various methods of AR suppression 
have similar efficacy in vitro. We conclude that patients with AR-expressing PCa can 
benefit from apalutamide or other AR suppressing treatment in addition to EBRT.  
Previous preclinical studies have investigated the molecular mechanism of 
radiosensitization by ADT and discovered an interplay between AR-signaling and the 
DNA repair machinery (7, 8, 10, 11, 16). However, opposing conclusions were drawn 
from these studies about the DNA repair pathways that cause the radiosensitization. 
Studies reported a functional link between AR-signaling and HR repair and synthetic 
lethality in combinations of AR inhibitors and PARP inhibitors in PCa. Enzalutamide 
suppressed the expression of the HR protein RAD51 in androgen-dependent PCa cells 
(10) and HR efficiency, measured by a functional HR assay, was indeed significantly 
reduced by AR suppression (10, 11, 16). We found that reduced RAD51 expression and 
compromised HR could be explained by a reduced fraction of S/G2 phase cells. Such 
cell cycle analyses were not included in their studies, which precludes definitive 
conclusions. Asim et al. showed that IR-induced RAD51 foci formation in Ki67-
positive PCa cells were strongly decreased in patient biopsies who received ADT (11). 
This is seemingly in contrast with our results that equal numbers of RAD51 foci were 
detected in EdU-positive cells after AR suppression. However, this discrepancy can be 
explained by the difference in detection of proliferating cells: EdU labels only S-phase 
cells, whereas Ki67 is present in all cycling cells. It has even been reported to persist 
for several days after cells have ceased to proliferate (17). Ki67 positive cells may thus 
be primarily G1 phase cells that do not form RAD51 foci nor perform HR. Together, 
our data indicate that the HR pathway is not directly regulated by AR-signaling, but 
HR might be reduced on a cell population level caused by a change of the cell cycle 
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profile.  
After excluding AR regulated HR repair, we further investigated the NHEJ repair 
pathway. A previous study discovered that AR directly regulates the level and function 
of the NHEJ factor DNA-PKcs (7). Our data confirmed this observation and showed 
that AR suppression reduced DNA-PKcs levels in both androgen-dependent and CRPC 
cells. Downregulation of DNA-PKcs is further supported by the low staining intensity 
of DNA-PKcs in PCa tissue after combined castration and radiotherapy when compared 
with radiotherapy alone (18). These data were further confirmed by siRNA knockdown 
of DNA-PKcs indeed resulted in a similar level of radiosensitization and delayed DNA 
repair in AR-expressing cells. We conclude that NHEJ is directly regulated by AR-
signaling and that downregulation of DNA-PKcs expression contributes to the 
radiosensitization induced by AR suppression. 
Previous preclinical studies reported the synthetic lethality between AR inhibitors 
and PARP inhibitors (10, 11). Unfortunately, the first randomized multicenter clinical 
trial failed to show a significant difference in prostate-specific antigen response rate 
and median progression-free survival between patients treated with abiraterone plus the 
PARP inhibitor veliparib compared to abiraterone acetate plus prednisone alone (19). 
This combination was based of the rationale that tumors with loss-of-function 
mutations in BRCA1/2 are deficient in HR repair, which makes them highly sensitive 
to PARP inhibition treatment (20, 21). Based on our finding that AR suppression causes 
reduced NHEJ, not HR, one would indeed expect a lack of efficacy from this 
combination treatment in an unselected PCa patient population. On the other hand, PCa 
patients harboring BRCA1/2 mutations could possibly benefit to a greater degree from 
combination of apalutamide and EBRT compared to BRCA1/2 wild type patient, as 
intrinsic HR repair defects in these patients plus compromised NHEJ repair by 
apalutamide will render the tumor cells exquisitely vulnerable to IR. 
Emerging preclinial and clinical studies show that AR variants (AR-Vs) can play 
an important role in the development of resistance to AR suppression treatment (22, 
23). AR-Vs lack the ligand-binding domain, and therefore are constitutively active, 
which consitutes a mechanism of resistance when androgen ligands are very low under 
ADT (22). Recently, studies reported that in genetically engineered R1-D567 cells 
(only expressing AR-Vs), and 22Rv1 cell line (expressing both AR and high AR-V7), 
combination of IR and AR suppression treatment, could not increase radiosensitivity 
via altering the AR mediated DDR (24). These studies imply that the expression of AR-
Vs in PCa cells may counteract the AR suppression-induced radiosensitization and 
patients with AR-V expression might not be eligible for such a combination regimen. 
It remains to be investigated whether a certain level of AR expression is a prerequisite 
for achieving radiosensitization by AR suppression treatments. These issues warrant 
further investigation with more PCa models. 
We did not find significant differences in response between ADT, enzalutamide 
and apalutamide treatment, probably because ADT in an in vitro setting is a simplified 
and optimal scenario, while effects in patients are less optimal due to adrenal androgen 
production being unaffected under ADT. Apalutamide has recently received FDA 
approval for the treatment of non-metastatic CRPC. Several clinical trials are underway 
  
to test the efficacy of apalutamide with EBRT (NCT03488810, NCT03503344, 
NCT02531516). The preclinical data presented here fully support the ongoing clinical 
trials. Furthermore, our study showed benefit of the combination in AR-expressing 
CRPC cells, a situation also found in patients with advanced metastatic disease that are 
progressive on ADT. Therefore, we propose that an alternative treatment approach 
should be considered for these patients, consisting of apalutamide in combination with 
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (25). The 
decreased DNA repair effectivity in the tumor, but not the normal tissue, should 
increase the therapeutic ratio in this setting. 
4. Materials and Methods  
4.1. Reagents  
Reagents were purchased from Sigma-Aldrich, unless otherwise specified. The 
following antibodies were used: AR (1:200, M4074, SPRING Bioscience, Pleasanton, 
CA, USA), RAD51 (1:10000, homemade, (26)), DNA-PKcs (1:1000, homemade (27)), 
phospho-histone H2AX (ser139) (γ-H2AX) (1:500, JBW301, Millipore, Darmstadt, 
Germany), 53BP1 (1:1000, NB100-904, Novus Biologicals, Novus Biologicals, 
Littleton, CO, USA), α-tubulin (1:10000, B-5-12, Sigma-Aldrich, Darmstadt, 
Germany), anti-rabbit/mouse Alexa Fluor 488/594 (1:1000, Life Technologies, 
Carlsbad, CA, USA). Apalutamide was a gift from Janssen-Cilag B.V., enzalutamide 
was purchased from Axon Medchem (Groningen, The Netherlands). Both compounds 
were diluted in dimethyl sulfoxide (DMSO) and used at a final concentration of 1μM. 
4.2. Cell lines  
DU145 and LNCaP cells were purchased from American Type Culture Collection 
(Manassas, VA, USA) and cultured as described (28, 29). PC346C, PC346C-DCC and 
PC346C-Flu1 cells were established in our laboratory and cultured as previously 
described (30). Composition of the cell culture medium and characteristics of each cell 
line can be found in supplementary table 1. All cells lines were authenticated for AR 
expression by western blot. Cells were regularly tested for mycoplasma infection, and 
kept into culture for maximum 25 passages after initiating the hormone 
sensitive/castration resistance phenotype.  
4.3. Irradiation (IR) 
Cells and tissue slices were irradiated with different X-ray doses using Xstrahl Cabinet 
Irradiator RS320 (195 kV, 10 mA, 1.67 Gy/min, Xstrahl Ltd. Camberley, UK). 
4.4. Cell growth assay 
Cell growth was measured using the sulforhodamine beta (SRB) assay. Briefly, all cells 
were plated in FNC coating mix (Athena Environmental Sciences) coated 96-well 
plates in 100 μl steroid-stripped medium (medium with dextran-coated charcoal-treated 
FCS: DCC). The next day, 100 μl of culture medium were added either alone (ADT 
condition) or supplemented with R1881 (0.1 nM, control condition) or R1881 (0.1 nM) 
plus apalutamide/enzalutamide (1 uM, apalutamide or enzalutamide condition) 24 h 
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profile.  
After excluding AR regulated HR repair, we further investigated the NHEJ repair 
pathway. A previous study discovered that AR directly regulates the level and function 
of the NHEJ factor DNA-PKcs (7). Our data confirmed this observation and showed 
that AR suppression reduced DNA-PKcs levels in both androgen-dependent and CRPC 
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of DNA-PKcs indeed resulted in a similar level of radiosensitization and delayed DNA 
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to test the efficacy of apalutamide with EBRT (NCT03488810, NCT03503344, 
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Germany), anti-rabbit/mouse Alexa Fluor 488/594 (1:1000, Life Technologies, 
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(Manassas, VA, USA) and cultured as described (28, 29). PC346C, PC346C-DCC and 
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described (30). Composition of the cell culture medium and characteristics of each cell 
line can be found in supplementary table 1. All cells lines were authenticated for AR 
expression by western blot. Cells were regularly tested for mycoplasma infection, and 
kept into culture for maximum 25 passages after initiating the hormone 
sensitive/castration resistance phenotype.  
4.3. Irradiation (IR) 
Cells and tissue slices were irradiated with different X-ray doses using Xstrahl Cabinet 
Irradiator RS320 (195 kV, 10 mA, 1.67 Gy/min, Xstrahl Ltd. Camberley, UK). 
4.4. Cell growth assay 
Cell growth was measured using the sulforhodamine beta (SRB) assay. Briefly, all cells 
were plated in FNC coating mix (Athena Environmental Sciences) coated 96-well 
plates in 100 μl steroid-stripped medium (medium with dextran-coated charcoal-treated 
FCS: DCC). The next day, 100 μl of culture medium were added either alone (ADT 
condition) or supplemented with R1881 (0.1 nM, control condition) or R1881 (0.1 nM) 
plus apalutamide/enzalutamide (1 uM, apalutamide or enzalutamide condition) 24 h 
before irradiation (IR). Cells were allowed to grow until different time points, and fixed 
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and stained with SRB as previously described (31). Absorbance was measured at 560 
nm using a GloMax®-Multi Detection System (Promega, Madison, WI, USA).  
4.5. Immunofluorescent staining on cells 
γ-H2AX and 53BP1 staining was performed as previously described (31). Briefly, cells 
were seeded in DCC medium overnight on coverslips and treated with various anti-
androgen or control (R1881) treatments for 24 h before IR. Cells were fixed with 2% 
paraformaldehyde (PFA) after 1 h and 24 h. Following permeabilization and blocking, 
cells were incubated with anti-γH2AX and anti-53BP1 antibodies overnight, and 
secondary antibodies. EdU/RAD51 co-staining was done as previous reported (32). 
Briefly, 5-ethynyl-2'-deoxyuridine (EdU, Thermo Fisher Scientific, Carlsbad, CA, 
USA) at a concentration of 3 μg/ml was added to the cells 30 min before fixation. Pre-
extraction was performed in Triton X-100 buffer (0.5% Triton X-100, 20 mM Hepes-
KOH, pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose) at room temperature (RT) 
for 1 min before fixation. After permeabilization and blocking, cells were incubated 
with anti-RAD51 antibody and subsequently incubated with secondary antibody 
followed by Click-iT Alexa Fluor 594 cocktail buffer for 30 min. 
4.6. Cell cycle analysis 
Cell cycle distribution was measured by flowcytometry (33). Briefly, cells were seeded 
in DCC medium overnight and treated with various antiandrogen treatments for 24 h 
before IR. EdU at a concentration of 3 μg/ml was added to the culture medium 30 min 
before fixation and cells were fixed with ice-cold 70% ethanol 24 h post-IR. Cells were 
washed with phosphate-buffered saline (PBS) and permeabilized in 0.1% Triton X-100 
in PBS for 5 min at RT. Subsequently cells were incubated in Click-iT Alexa Fluor 594 
cocktail buffer for 30 min, and then cells were resuspended in 1 μg/ml DAPI and 0.1 
mg/ml RNase (Roche Life Sciences, Mannheim, Germany) in PBS. Cell cycle 
distribution was measured using a LSRFORTESSA FACS machine (BD Bioscience, 
San Jose, CA, USA). 
4.7. Tissue slice culture  
All animal experiments were approved by the Animal Welfare Committee of the 
Erasmus MC, and all experiments were conducted in accordance with accepted 
guidelines (permit AVD101002017867, 25 September 2017). PC295 PDXs were 
previously established in our laboratory (34). PDX tumors were excised, sliced and 
cultured as previously reported (14). Briefly, 300 μm slices were cultured in advanced 
DMEM/F12 (ThermoFisher Scientific, Carlsbad, CA, USA) medium in 6 well plates 
on a Rocking Table (Luckham 200 Ltd., West Sussex, UK) and one third of medium 
was refreshed daily. Slices were pretreated with apalutamide or DMSO control for 2 h 
and subsequently irradiated with a dose of 2 Gy. At different time points, slices were 
harvested and fixed in 10% neutral buffered formalin for 24h at RT, embedded in 
paraffin and 4 μm sections were made for further analysis. EdU (3 μg/ml) was added to 
the tissue slice culture medium 2 h before fixation.  
4.8. Tissue section TUNEL and EdU Click-iT assays 
EdU at a concentration of 3 μg/ml was added to the tissue slice culture medium 2 h 
  
before fixation. Simultaneous TUNEL and EdU staining was performed as described 
previously (35). Briefly, tissue sections were deparaffinized in xylene followed by 
rehydration in graded alcohols and then blocked with PBS 3% BSA. TUNEL reaction 
was performed using In Situ Cell Death Detection Kit (Roche Life Sciences, Penzberg, 
Germany) after which the sections were incubated with Click-iT Alexa Fluor 594 
(Invitrogen, Carlsbad, CA, USA) cocktail buffer for 30 min.  
4.9. Tissue section Hematoxylin & eosin (H&E)  
Histological tumor architecture was examined by H&E staining as previously described 
(14). Briefly, sections were deparaffinized in xylene followed by rehydration in graded 
alcohols and staining with hematoxylin and eosin (14). 
4.10. Tissue section immunohistochemical staining 
Sections were deparaffinized in xylene followed by rehydration in graded alcohols. 
Antigen retrieval was performed with target retrieval buffer (pH 6, Dako, Glostrup, 
Denmark). Sections were treated with 3% hydrogen peroxide solution in methanol at 
RT for 20 min, followed by incubation in 5% BSA in PBS for 30 min at RT. Sections 
were incubated with anti-AR antibodies overnight, and horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG secondary antibody (1:100, Dako) for 1 h at RT. AR positive 
cells were visualized using diaminobenzidine (DAB) staining kit (Agilent, Santa Clara, 
CA, USA) and hematoxylin counter staining. 
4.11. Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) was performed as previously described (36). 
Briefly, cells were embedded in 2% agarose plugs and lysed following 15 Gy of IR (15 
Gy is commonly used for the PFGE assay since 2 Gy is too low to detect clear bands 
of DSBs). Electrophoresis was performed at 14 °C in 0.9% pulse-field certified agarose 
(Bio-Rad, Hercules, CA, USA) in a Bio-Rad Chef DR III system (Bio-Rad, La Jolla, 
CA, USA). The gel was stained with ethidium bromide and imaged on a UVITEC gel 
documentation system (UVItec, Cambridge, UK). DSBs bands were quantified using 
ImageJ (version 1.52, open source software via https://imagej.nih.gov/ij/index.html) 
with background subtracted and normalized to unsaturated signals of intact DNA. For 
each treatment, these values were normalized against their respective untreated controls 
to obtain the fold-change in DSBs. 
4.12. HR assay 
DR-GFP assay was performed to measure HR as previous described (33). Briefly, cells 
were transfected with 1.5 μg of DR-GFP plasmid and an I-SceI expression vector or 
empty vector according to the manufacturer’s protocol (FuGENE HD (Promega) for 
LNCaP and Lipofectamine 3000 (Invitrogen) for PC346C-Flu1). Transfected cells were 
cultured in medium containing apalutamide or DMSO control for 48 h. BRCA1 
knockdown was used as a positive control. GFP expression was analyzed by flow 
cytometry (LSRFORTESSA, BD Bioscience, San Jose, CA, USA). 
4.13. Western blot  
Cells were lysed and lysates were resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA, USA), transferred to 
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and stained with SRB as previously described (31). Absorbance was measured at 560 
nm using a GloMax®-Multi Detection System (Promega, Madison, WI, USA).  
4.5. Immunofluorescent staining on cells 
γ-H2AX and 53BP1 staining was performed as previously described (31). Briefly, cells 
were seeded in DCC medium overnight on coverslips and treated with various anti-
androgen or control (R1881) treatments for 24 h before IR. Cells were fixed with 2% 
paraformaldehyde (PFA) after 1 h and 24 h. Following permeabilization and blocking, 
cells were incubated with anti-γH2AX and anti-53BP1 antibodies overnight, and 
secondary antibodies. EdU/RAD51 co-staining was done as previous reported (32). 
Briefly, 5-ethynyl-2'-deoxyuridine (EdU, Thermo Fisher Scientific, Carlsbad, CA, 
USA) at a concentration of 3 μg/ml was added to the cells 30 min before fixation. Pre-
extraction was performed in Triton X-100 buffer (0.5% Triton X-100, 20 mM Hepes-
KOH, pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose) at room temperature (RT) 
for 1 min before fixation. After permeabilization and blocking, cells were incubated 
with anti-RAD51 antibody and subsequently incubated with secondary antibody 
followed by Click-iT Alexa Fluor 594 cocktail buffer for 30 min. 
4.6. Cell cycle analysis 
Cell cycle distribution was measured by flowcytometry (33). Briefly, cells were seeded 
in DCC medium overnight and treated with various antiandrogen treatments for 24 h 
before IR. EdU at a concentration of 3 μg/ml was added to the culture medium 30 min 
before fixation and cells were fixed with ice-cold 70% ethanol 24 h post-IR. Cells were 
washed with phosphate-buffered saline (PBS) and permeabilized in 0.1% Triton X-100 
in PBS for 5 min at RT. Subsequently cells were incubated in Click-iT Alexa Fluor 594 
cocktail buffer for 30 min, and then cells were resuspended in 1 μg/ml DAPI and 0.1 
mg/ml RNase (Roche Life Sciences, Mannheim, Germany) in PBS. Cell cycle 
distribution was measured using a LSRFORTESSA FACS machine (BD Bioscience, 
San Jose, CA, USA). 
4.7. Tissue slice culture  
All animal experiments were approved by the Animal Welfare Committee of the 
Erasmus MC, and all experiments were conducted in accordance with accepted 
guidelines (permit AVD101002017867, 25 September 2017). PC295 PDXs were 
previously established in our laboratory (34). PDX tumors were excised, sliced and 
cultured as previously reported (14). Briefly, 300 μm slices were cultured in advanced 
DMEM/F12 (ThermoFisher Scientific, Carlsbad, CA, USA) medium in 6 well plates 
on a Rocking Table (Luckham 200 Ltd., West Sussex, UK) and one third of medium 
was refreshed daily. Slices were pretreated with apalutamide or DMSO control for 2 h 
and subsequently irradiated with a dose of 2 Gy. At different time points, slices were 
harvested and fixed in 10% neutral buffered formalin for 24h at RT, embedded in 
paraffin and 4 μm sections were made for further analysis. EdU (3 μg/ml) was added to 
the tissue slice culture medium 2 h before fixation.  
4.8. Tissue section TUNEL and EdU Click-iT assays 
EdU at a concentration of 3 μg/ml was added to the tissue slice culture medium 2 h 
  
before fixation. Simultaneous TUNEL and EdU staining was performed as described 
previously (35). Briefly, tissue sections were deparaffinized in xylene followed by 
rehydration in graded alcohols and then blocked with PBS 3% BSA. TUNEL reaction 
was performed using In Situ Cell Death Detection Kit (Roche Life Sciences, Penzberg, 
Germany) after which the sections were incubated with Click-iT Alexa Fluor 594 
(Invitrogen, Carlsbad, CA, USA) cocktail buffer for 30 min.  
4.9. Tissue section Hematoxylin & eosin (H&E)  
Histological tumor architecture was examined by H&E staining as previously described 
(14). Briefly, sections were deparaffinized in xylene followed by rehydration in graded 
alcohols and staining with hematoxylin and eosin (14). 
4.10. Tissue section immunohistochemical staining 
Sections were deparaffinized in xylene followed by rehydration in graded alcohols. 
Antigen retrieval was performed with target retrieval buffer (pH 6, Dako, Glostrup, 
Denmark). Sections were treated with 3% hydrogen peroxide solution in methanol at 
RT for 20 min, followed by incubation in 5% BSA in PBS for 30 min at RT. Sections 
were incubated with anti-AR antibodies overnight, and horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG secondary antibody (1:100, Dako) for 1 h at RT. AR positive 
cells were visualized using diaminobenzidine (DAB) staining kit (Agilent, Santa Clara, 
CA, USA) and hematoxylin counter staining. 
4.11. Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) was performed as previously described (36). 
Briefly, cells were embedded in 2% agarose plugs and lysed following 15 Gy of IR (15 
Gy is commonly used for the PFGE assay since 2 Gy is too low to detect clear bands 
of DSBs). Electrophoresis was performed at 14 °C in 0.9% pulse-field certified agarose 
(Bio-Rad, Hercules, CA, USA) in a Bio-Rad Chef DR III system (Bio-Rad, La Jolla, 
CA, USA). The gel was stained with ethidium bromide and imaged on a UVITEC gel 
documentation system (UVItec, Cambridge, UK). DSBs bands were quantified using 
ImageJ (version 1.52, open source software via https://imagej.nih.gov/ij/index.html) 
with background subtracted and normalized to unsaturated signals of intact DNA. For 
each treatment, these values were normalized against their respective untreated controls 
to obtain the fold-change in DSBs. 
4.12. HR assay 
DR-GFP assay was performed to measure HR as previous described (33). Briefly, cells 
were transfected with 1.5 μg of DR-GFP plasmid and an I-SceI expression vector or 
empty vector according to the manufacturer’s protocol (FuGENE HD (Promega) for 
LNCaP and Lipofectamine 3000 (Invitrogen) for PC346C-Flu1). Transfected cells were 
cultured in medium containing apalutamide or DMSO control for 48 h. BRCA1 
knockdown was used as a positive control. GFP expression was analyzed by flow 
cytometry (LSRFORTESSA, BD Bioscience, San Jose, CA, USA). 
4.13. Western blot  
Cells were lysed and lysates were resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA, USA), transferred to 
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polyvinylidene difluoride membranes, and analyzed using antibodies described above. 
Quantification was conducted using ImageJ software. 
4.14. RNA Interference 
PC346C-Flu1 cells were transfected with either control or DNA-PKcs siRNA 
(Dharmacon, Lafayette, CO, USA) using Lipofectamine RNAi MAX (Life 
Technologies, Carlsbad, CA, USA). Transfected cells were cultured for 48 h and then 
treated as specified. 
4.15. Image acquisition and quantification 
For 53BP1, γH2AX, RAD51 foci quantification, at least 3 random fields of view of Z-
stack images were captured with a LSM700 confocal microscope (Zeiss, Oberkochen, 
Germany) and quantified as previously described (32). AR and H&E was imaged with 
a light microscope (Olympus, Tokyo, Japan) and 4 fields of view from each section 
were analyzed. For EdU and TUNEL quantification, 10 random images from each 
tissue slice section were generated using a Leica fluorescence microscope (DM4000b, 
Wetzlar, Germany) and quantified using the Otsu’s algorithm in a Matlab based 
software as previous reported (14). AR expression was quantified by using Image J 
software as previous described (14).  
4.16. Statistical analysis 
Experiments were performed in duplicate (foci kinetics) or triplicate (all other 
experiments). One-way ANOVA test was used to compare more than two groups and 
unpaired student's t-test was used to analyze the differences between two groups. 
Statistical analysis and generation of graphs was performed using GraphPad Prism 6.0 
(GraphPad, La Jolla, CA, USA). 
5. Conclusions 
In summary, we demonstrate for the first time that the next-generation AR inhibitor 
apalutamide acts as a radiosensitizer in AR-expressing androgen-dependent PCa and 
CRPC models. This radiosensitization is caused by inhibition of DNA repair by NHEJ, 
not HR. Our results suggest that apalutamide can not only be used in combination with 
EBRT for the treatment of androgen-dependent localized PCa, but also for AR-
expressing CRPC patients. 
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Supplementary Materials:  
 
Supplementary Figure 1. 
Quantification of γH2AX and 53BP1 foci in cell lines treated with AR suppression for 48 h. 
Each data point represents one cell, average and SEM are indicated, ns, non-significant. ADT, 
androgen deprivation treatment; APA, apalutamide; ENZA, enzalutamide. 
 
Supplementary Figure 2.  
LNCaP, PC346C and PC346C-Flu1 cells were treated with AR suppression for 24 h followed 
by IR (2 Gy). Cell samples were collected 24 h post-IR and cell cycle was determined by flow 
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cytometry. Average and SD were indicated. *P < 0.05, ns, non-significant. ADT, androgen 
deprivation treatment; APA, apalutamide; ENZA, enzalutamide. 
 
 
Supplementary Figure 3.  
Full blots and quantification of the band of the western blot experiments shown in Figure 4A 
and 5A. 
  
  
Supplementary Table 1 
Cell 
lines 
DU145 LNCaP PC346C PC346C-DCC PC346C-Flu1 
Culture 
Medium 
 
RPMI 
1640 
FCS 
(10%) 
PS 
RPMI 
1640 
FCS 
(10%) 
PS 
DMEM/Ham’s F12 
BSA (0.01%) 
FCS (2%) 
Epidermal growth factor (10 
ng/mL) 
Insulin-transferrin-selenium 
(1%) 
Hydrocortison 
(0.5 µg/mL) 
Triiodothyronine 
(1 nM) 
Phosphoethanolamine 
(0.1 mM) 
Cholera toxin 
(50 ng/mL) 
Fibronectin 
(100 ng/mL) 
Fetuine (20 µg/mL) 
R1881 (0.1 nM) 
PS 
DMEM/Ham’s F12 
BSA (0.01%) 
DCC (2%) 
Epidermal growth factor 
(10 ng/mL) 
Insulin-transferrin-
selenium (1%) 
Hydrocortison 
(0.5 µg/mL) 
Triiodothyronine 
(1 nM) 
Phosphoethanolamine 
(0.1 mM) 
Cholera toxin 
(50 ng/mL) 
Fibronectin 
(100 ng/mL) 
Fetuine (20 µg/mL) 
R1881 (0.1 nM) 
PS 
PC346C-DCC 
medium 
plus 
OH-flutamide 
(1 µM) 
AR - + + - ++ 
p53 Missense 
Mutation 
Silent WT WT WT 
BRCA2 Missense 
Mutation 
WT WT WT WT 
PTEN WT Frame 
Shift 
Deletion 
Nonsense mutation Nonsense mutation Nonsense 
mutation 
AR: androgen receptor; BRCA2: breast cancer 2; PTEN: Phosphatase and tensin homolog; PS: 
Penicillin/streptomycin (100 U/mL, 100 µg/mL); FCS: Fetal calf serum; DCC: charcoal dextran-
stripped serum; WT: wild type. For DU145 and LNCaP, data was acquired from The Cancer Cell 
Line Encyclopedia (CCLE) https://portals.broadinstitute.org/ccle. 
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Prostate cancer (PCa) remains a heavy burden in current healthcare as it is the most 
common non-skin cancer and fifth leading cause of cancer-related death in males. 
Despite progress in understanding the biology of PCa and developing new drugs and 
therapeutic strategies, advanced stage PCa continues to be incurable and development 
of drug resistance remains a crucial issue. Extensive research has aimed to further 
understand PCa, including developing more reliable preclinical models, increasing 
treatment efficacy, selecting best patients for certain treatment regimen and predicting 
treatment response. The role of the DNA damage response (DDR) has drawn particular 
attention in recent years as an increasing number of PCa patients harboring DDR defect 
is being identified. These findings may have important implications for their treatment, 
since new DDR-targeting compounds show great potential for precision medicine. 
Furthermore, the recently discovered crosstalk between the DDR machinery and 
androgen receptor (AR) signaling opens a new array of possible strategies to enhance 
treatment efficacy. 
This thesis describes the development of novel 3D in vitro PCa models, analysis of 
DNA double-strands break (DSB) repair in PCa and how the DDR may impact PCa 
treatment. Preclinical research of PCa depends heavily on a limited number of 
conventional 2D cell lines. Although their homogeneity and ease of handling makes 
them valuable models for high-throughput experiments, lack of complex architecture 
and cell interaction makes them “unrepresentative’’ models and may lead to a failure 
when transitioning a new treatment from bench to clinic. To overcome this, two distinct 
methods to culture 3D PCa tumor in vitro are being discussed in this thesis. The first 
method involves the generation and culture of organotypic PCa tumor slices (chapter 
3). Organotypic indicates these tumor slices retain morphology and function of the 
tumor of origin in vivo. Culture conditions have been optimized such that tissue viability, 
proliferation capacity and prostatic characteristics have been maintained up to at least 
6 days. Robust marker and analytical tools for cell proliferation and cell apoptosis were 
used as surrogates to assess response to ex vivo anti-androgen and poly(ADP-ribose) 
polymerase (PARP) inhibitor treatment. Importantly, the response to different tumor 
genotypes, represented by different PDXs were validated, and hence provide evidence 
that ex vivo drug testing can indeed predict in vivo responses. The established tissue 
slices culture system can be extended for testing novel compounds relevant to PCa 
treatment. Maintenance of primary PCa tumors has been challenging probably due to 
the slow growing characteristics and fast proliferation of basal cells. Also, obtaining 
aggressive metastatic PCa material is met with limitations as metastatic disease is 
predominantly found in bone restricting easy access. Nowadays, prostate-specific 
membrane antigen (PSMA) guided biopsy and salvage lymphadenectomy is reported, 
which may offer new opportunities for acquiring aggressive PCa material for ex vivo 
drug response tests. Our tissue slice culture platform for PCa defined in this thesis may 
be helpful to standardize ex vivo culturing of patient material and shows the promising 
future of personalized medicine in PCa treatment.  
Besides analyzing treatment effects by directly assessing tumor slices themselves, 
we investigated the extracellular vesicles (EVs) secreted from tissue slices in culture 
medium, and characterized their abundance and RNA content compared to the original 
tissue slices (chapter 4). As a promising field in liquid biopsy, EVs has drawn particular 
interest in recent years as they are able to capture tumor heterogeneity and they can be 
reassessed periodically. We identified abundant presence of EVs in the tissue slice 
culture media, from which RNAs could be obtained. Importantly, we detected that gene 
expression alterations after anti-androgen treatment were highly similar between tumor 
  
 
 
slices and EVs. This implies that EVs may reflect the biological effects on the original 
cells in the tumor slice and that this may yield reliable markers for monitoring treatment 
response over time in the same tumor slice. Evaluating these EVs in tissue models 
allows the determination of tissue origin of these factors, which is difficult to 
accomplish in vivo. Most in vivo studies on EVs obtained from blood, urine and 
malignant ascites are difficult to interpret because of multiple potential cellular sources 
of these EVs. In addition, several challenges present when isolating EVs from body 
fluid, such as limited availability of biospecimens and the presence of high-abundance 
proteins and lipoprotein particles. Increasing evidence showed that EVs play a crucial 
role in cell-to-cell communication, however, isolated tumor cells do not adequately 
recapitulate important aspects of tissue function related to cell-to-cell communications 
in vivo. In such case, 3D models have major value in investigating the role of EVs in 
cancer development and testing anti-cancer compounds under controlled laboratory 
conditions. Different types of vesicles, such as exosomes, microvesicles and apoptotic 
bodies, were defined by biogenesis and roughly correlated with their size. However, the 
classification of individual EVs is difficult and the origin of the individual EVs in cell 
culture medium and body fluids cannot yet be determined. Whether there are functional 
differences between EV subtypes is not known yet, and it is unclear how this might 
affect current knowledge of EVs. Thus, it is imperative to overcome the technical 
challenges and standardize the procedures that associated with homogenous EV 
purification and accurate quantification.  
In addition to organotypic tissue slices culture, the second method first dissociates 
the tumors enzymatically and mechanically, followed by embedding dissociated cells 
into a 3D matrix. In such case, tumor cells will grow as tumor organoids. PCa organoids 
have been proven difficult to establish and very little data are available comparing PCa 
organoids to the in vivo tumors and thus it is unclear how well these PCa organoids 
recapitulate structural and functional aspect of their original tumors. In chapter 5, we 
investigated the irradiation effects on PCa organoids and compared them to their 
matched tissue slices. Tumor morphology and prostatic characteristics are well 
preserved in organoids, with AR expression and prostate-specific antigen (PSA) 
secretion. A comparable response to irradiation between organoids and tissue slices was 
observed in terms of tumor cell proliferation, apoptosis and DDR kinetics, suggesting 
that PCa organoids may be used for testing irradiation-drug combinations in a medium 
throughput screening. This result warrants further validation with more tumor models 
and the in vitro response should be compared to the in vivo effect in order to get a more 
complete view. As generally acknowledged, PCa research has been hampered by the 
lack of suitable in vitro model systems. Although powerful in vivo models are available, 
these are often expensive and time-consuming. In this thesis, we have described two 
types of novel in vitro models. Compared to the tissue slice model, the organoid model 
is not restricted to short-term culture and limited proliferation capacity and therefore 
allows for larger-scale screening once organoid lines have been established. 
Nevertheless, organoids also have their limitations, as they still lack stroma and immune 
cells, while this may partly be preserved in tissue slices. Compared to organoids, assays 
based on tissue slices can be done within a few days to weeks after obtaining material, 
which is compatible with regular clinical decision making and could be incorporated 
into the diagnostic routine before start of treatment. Thus, models should be chosen 
based on the specific situation and research question.  
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treatment efficacy, selecting best patients for certain treatment regimen and predicting 
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DNA double-strands break (DSB) repair in PCa and how the DDR may impact PCa 
treatment. Preclinical research of PCa depends heavily on a limited number of 
conventional 2D cell lines. Although their homogeneity and ease of handling makes 
them valuable models for high-throughput experiments, lack of complex architecture 
and cell interaction makes them “unrepresentative’’ models and may lead to a failure 
when transitioning a new treatment from bench to clinic. To overcome this, two distinct 
methods to culture 3D PCa tumor in vitro are being discussed in this thesis. The first 
method involves the generation and culture of organotypic PCa tumor slices (chapter 
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Besides analyzing treatment effects by directly assessing tumor slices themselves, 
we investigated the extracellular vesicles (EVs) secreted from tissue slices in culture 
medium, and characterized their abundance and RNA content compared to the original 
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slices and EVs. This implies that EVs may reflect the biological effects on the original 
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124
Chapter 7
  
 
 
Radiation therapy, the first-line treatment for localized PCa, is commonly combined 
with adjuvant androgen deprivation therapy (ADT) for high-risk PCa patients, as the 
combination regimen significantly improves overall PCa-related survival. Previous 
preclinical studies have investigated the molecular mechanism of radiosensitization by 
ADT and suggested a connection between AR-signaling and the DDR machinery. 
However, opposing conclusions were drawn from these studies about the DNA repair 
pathways that cause the radiosensitization. In chapter 6, we tested the radiosensitizing 
effect of next generation anti-androgen apalutamide and ADT in a preclinical PCa 
progression cell model and an androgen-dependent tissue slices model. We demonstrate 
that these treatments can act as a radiosensitizer in both AR-expressing preclinical PCa 
models. The mechanism of action causing this radiosensitization involves regulation of 
the non-homologous end-joining (NHEJ) DNA repair pathway by AR-signaling. We 
resolved the controversy by providing solid evidence that the homologous 
recombination (HR) repair is not directly regulated by AR signaling. HR reduction upon 
anti-androgen treatment on a cell population level was caused by a change of the cell 
cycle profile, but the few cells in S phase were still HR proficient. Our data also suggest 
that PCa patients harboring HR mutations could possibly benefit to a greater degree 
from combination of apalutamide and irradiation compared to HR wild type patient, as 
intrinsic HR repair defects in these patients plus compromised NHEJ repair by 
apalutamide will render the tumor cells exquisitely vulnerable to irradiation. It is to be 
expected that due to increased use of next generation sequencing approaches, it is likely 
that more PCa patients with HR defects will be detected. In early stage, for PCa patients 
harboring HR defects, such as BRCA1 or 2 mutations, a greater benefit can be expected 
from such combination treatment. If the disease progresses, these patients can then be 
offered with PARP inhibitors treatment. However, the implementation and 
standardization of genomic testing still remains a major challenge. Besides blood based 
germline mutation and biopsy based somatic mutation testing, new studies are looking 
into circulating tumor cells or cell-free DNA based detection of a panel of clinically 
actionable genes to select eligible patients. 
Overall, this thesis first describes the development and application of 3D in vitro 
PCa models: tissue slices culture and organoids culture. These 3D platform for PCa 
defined in this thesis may be helpful to standardize ex vivo culturing of patient material 
and shows the promising future of personalized medicine in PCa treatment. Next, the 
abundance and RNA content of EVs secreted from tissue slices in culture medium were 
analyzed, showing that EVs may reflect the biological effects on the original cells in 
the tumor slice and that this may yield reliable markers for monitoring treatment 
response over time in the same tumor slice. Lastly, using PCa progression cell model 
and tissue slices model, we demonstrate that AR suppression treatments can act as a 
radiosensitizer in both AR-expressing preclinical PCa models and the mechanism of 
action causing this radiosensitization involves regulation of the NHEJ DNA repair. The 
studies in this thesis provide new strategies for generation of novel 3D in vitro PCa 
model and broaden our understanding of DDR defects and AR-DDR interplay in PCa, 
this knowledge can be used to improve diagnostic, prognostic and therapeutic 
approaches for PCa management. 
 
 
  
  
 
 
Nederlandse samenvatting 
Prostaatkanker is de meest voorkomende vorm van kanker na huidkanker en staat in de 
top 5 van het hoogste aantal kanker-gerelateerde sterfgevallen in mannen. 
Prostaatkanker legt dan ook een zware druk op de gezondheidszorg. Prostaatkanker is 
nog steeds ongeneeslijk bij uitgezaaide ziekte, ondanks beter begrip van de 
fundamentele processen van prostaatkanker biologie en de ontwikkeling van nieuwe 
medicijnen en therapeutische strategieën. Dit komt mede doordat patiënten resistentie 
ontwikkelen tegen de behandelingen. Er is in de afgelopen jaren uitgebreid onderzoek 
gedaan om prostaatkanker beter te begrijpen en tehandelen, door het ontwikkelen van 
ontwikkeling van betrouwbare preklinische modellen, verhoging van therapeutische 
effectiviteit, persoonsgerichte therapie en het voorspellen van therapie effectiviteit. Met 
name de rol van de DNA schade response (DDR) heeft veel aandacht getrokken in de 
afgelopen jaren, omdat er DDR-defecten gevonden worden in prostaatkanker patiënten. 
Dit kan impact hebben op de behandelkeuze, aangezien DDR-gerichte medicijnen veel 
potentie hebben voor persoonsgerichte behandeling. Tevens zorgt de recent ontdekte 
interactie tussen de DDR en androgenen receptor (AR) signalering voor een groot aantal 
nieuwe mogelijke strategieën voor therapieverbetering. 
Dit proefschrift beschrijft de ontwikkeling van nieuwe 3D in vitro prostaatkanker 
modellen, analyse van DNA dubbelstrengs breuk (DSB) reparatie mechanismen en de 
gevolg van de DDR op prostaatkanker behandeling. Preklinisch onderzoek naar 
prostaatkanker wordt voornamelijk uitgevoerd met behulp van een beperkt aantal 
traditionele 2D tumorcellijnen. De homogeniteit en gebruiksgemak maakt deze 
cellijnen erg waardevolle modellen voor high-throughput experimenten. Ze hebben 
echter geen complexe samenstelling en cel-tot-cel interacties zodat dit niet altijd goede 
representatieve modellen zijn wat ertoe kan leiden dat ontwikkelingen (bv nieuw 
ontwikkelde medicijnen) niet altijd makkelijk van het lab naar de kliniek vertaald 
kunnen worden. Om dit probleem op te lossen, worden er in dit proefschrift twee 
verschillende 3D in vitro modellen besproken. Hoofdstuk 3 bespreekt de ontwikkeling 
en analyse van organotypische prostaatkanker tumorplakjes. Deze weefselplakjes 
behouden de morfologie en functie van de originele tumor. De kweekcondities zijn 
geoptimaliseerd zodat de weefselplakjes in leven blijven, hun prolifererende capaciteit 
behouden en verdere prostaatkanker karakteristieken behouden voor minimaal 6 dagen. 
Verscheidene specifieke analyse methoden voor de detectie van proliferatie en celdood 
werden gebruikt om de respons op ex vivo anti-androgenen therapie en poly-(ADP-
ribose)-polymerase (PARP) remmers. Deze ex vivo responsen waren vergelijkbaar met 
in vivo responsen; weefselplakjes kunnen een goed model systeem zijn om de 
effectiviteit van therapieën te meten. Tevens opent dit deuren voor het gebruik van 
primaire humane tumorplakjes voor persoonsgerichte therapie selectie. 
Verder hebben we ook extracellulaire vesicles (EVs), die uitgescheiden worden 
door de weefselplakjes in het kweekmedium, geanalyseerd. Van deze EVs hebben we 
de RNA inhoud vergeleken met de originele weefselplakjes (hoofdstuk 4). De 
afgelopen jaren is er in het veld van ‘vloeibare biopten’ veel aandacht voor EVs omdat 
ze overeenkomen met de tumor heterogeniteit en ze zijn periodiek opnieuw te 
beoordelen. Wij hebben een grote hoeveelheid EVs gemeten in het kweekmedium en 
daaruit RNA geïsoleerd. Veranderingen in genexpressie na antiandrogeen therapie 
waren hetzelfde in de EVs en de weefselplakjes. Dit impliceert dat effecten van de 
tumor ook gemeten kunnen worden in EVs en dat EVs dus een betrouwbare marker 
kunnen zijn in de weefselplakjes therapieresponsen in de tijd te meten. 
Naast weefselplakjes zijn er andere in vitro 3D modellen beschikbaar voor 
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analyzed, showing that EVs may reflect the biological effects on the original cells in 
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response over time in the same tumor slice. Lastly, using PCa progression cell model 
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radiosensitizer in both AR-expressing preclinical PCa models and the mechanism of 
action causing this radiosensitization involves regulation of the NHEJ DNA repair. The 
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prostaatkanker onderzoek, waaronder tumor organoïden. Hiervoor worden tumoren 
enzymatisch en mechanisch gedissocieerd en ingebed in een 3D matrix zodat ze als 
sferoïde kunnen groeien. Prostaatkanker organoïden zijn een nieuw modelsysteem en 
het is dus nog volledig onbekend hoe goed deze organoïden de structuur en functie van 
de oorspronkelijke tumor weergeven. In hoofdstuk 5 onderzoeken we de effecten van 
ioniserende straling in prostaatkanker organoïden en vergelijken deze met de effecten 
in bijbehorende weefselplakjes. Weefsel morfologie en prostaat kanker karakteristieken 
worden goed behouden in organoïden, zoals AR expressie en prostaat-specifiek antigen 
(PSA) uitscheiding. Organoïden en weefselplakjes reageren vergelijkbaar op 
ioniserende straling (proliferatie, apoptose, DDR kinetiek), wat zou kunnen betekenen 
dat dat prostaatkanker organoïden mogelijk gebruikt kunnen worden voor het testen 
van stralings-gerelateerde behandelingen. 
Radiotherapie is de eerstelijns therapie voor gelocaliseerd prostaatkanker en deze 
therapie wordt vaak gecombineerd met adjuvante hormoonbehandelingen omdat deze 
combinatie de overleving significant verbetert. Verscheidene preklinische studies 
hebben het mechanisme van radiosensitisatie van hormoonbehandelingen onderzocht 
en in deze studies werd een link gevonden tussen de AR-signalering en de DDR. Er 
werden echter tegenstrijdige conclusies getrokken over welke DNA reparatie route 
hiervoor verantwoordelijk is. In hoofdstuk 6 hebben we de effecten van de 
antiandrogeen apalutamide en andere hormoonbehandelingen getest in combinatie met 
radiotherapie in verscheidene prostaatkanker modellen. We laten zien dat deze 
behandelingen inderdaad de ioniserende stralingseffecten kunnen versterken in AR-
positieve preklinische modellen. Verder laten we zien dat dit effect veroorzaakt wordt 
door de niet-homologe end-joining (NHEJ) DNA reparatie route. Hiermee hebben we 
een controverse opgelost omdat we laten zien dat de homologe recombinatie (HR) DNA 
reparatie route niet direct gereguleerd wordt door de AR-signalering. Antiandrogeen 
behandeling onderdrukte HR in de gehele celpopulatie, maar dit werd veroorzaakt door 
een verandering in in het aantal cellen in celdeling, met minder S fase cellen. 
Prostaatkanker patiënten met een HR defect kunnen mogelijk beter reageren op een 
combinatie van apalutamide en radiotherapie in vergelijking met HR proficiënte 
patiënten, omdat intrinsieke HR reparatiedefecten in deze patiënten in combinatie met 
een aangetast NHEJ reparatie systeem (door apalutamide) de tumorcellen extra 
gevoelig zullen maken voor ioniserende straling. 
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Propositions  
1. PARP inhibitors will become part of the standard care for metastatic 
castration resistant prostate cancer patients who harbor homologous 
recombination deficiency. (this thesis) 
2. Ex vivo tumor slice culture is an ideal system for drug efficacy assessment. 
(this thesis) 
3. Extracellular vesicles may reflect the biological effects on the original tissue 
and thus could be used as a biomarker for monitoring treatment response. 
(this thesis) 
4. Biomarkers for intrinsic radiosensitivity are essential for prediction of the 
benefits of radiotherapy. (this thesis)  
5. Androgen receptor suppression treatments induced radiosensitization in 
prostate cancer is caused by inhibition of non-homologous end-joining 
repair, not homologous recombination repair. (this thesis)  
6. Future cancer treatments may be more realistically aiming for control of 
cancer making it a chronic disease rather than to reach cure.  
7. Artificially boosting the immune response is one of the most exciting, and 
promising advancements in the treatment of cancer (Immunotherapy, 2018). 
8. The first lesson when earning a PhD is to learn to accept disappointment. 
To realize this will bring your success even more rewarding. 
9. We necessarily draw conclusions based on the data we have, but we must 
acknowledge that this does not always represent truth. 
10. We really need to make good use of fragmented time, not to fragment our 
time. 
11. À cœur vaillant rien d'impossible. (Jacques Cœur) 
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